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ABSTRACT 
 
Bacterial or fungal infections in patients with cirrhosis: epidemiology across the world, 
definition of sepsis and predictors of post discharge outcomes 
 
Background and aims: Bacterial infections are frequently observed in patients with cirrhosis and 
confers a poor survival. In recent years an increase in mortality rate has been observed in patients 
with cirrhosis. In addition, an increase in the prevalence of multi drug (MDR) bacterial infections 
has been described, reducing the efficacy of commonly used antibiotics such as third generation 
cephalosporins. In this thesis we conducted 3 studies aimed to: a) provide data about epidemiology 
of infections across countries and continents; b) assess the ability of the new criteria for sepsis 
(Sepsis-3) in predicting poor outcomes in patients with cirrhosis and bacterial infections; c) to 
assess predictor of early readmission (within 30 days) and mid-term survival (6 months) after 
discharge for bacterial infections 
Methods: For the first study, we conducted a prospective, multicenter, intercontinental, cross 
sectional study including patients with cirrhosis and bacterial/fungal infections (1,302 patients). For 
the second study, we conducted a prospective cross sectional study in two cohort of patients 
(primary cohort [259 patients] and validation cohort [197 patients]). For the third study, patients 
discharged after a hospitalization for bacterial/fungal infections were followed up for 6 months (199 
patients). In all the 3 studies, demographic, clinical, laboratory and microbiological characteristics 
were collected at inclusion in the study and during the follow up. 
Results: In the first study we showed several differences among countries in the prevalence and the 
type of MDR bacterial infections, that were more prevalent in Indian or other Asian centers as well 
as in Southern American centers. These findings were associated with a significantly lower 
probability of microbiological susceptibility to antibiotic regimens suggested by the current 
guidelines. Remarkably, some infections were poorly treated even in countries with a low 
prevalence of MDR bacteria. The second study showed that Sepsis-3 criteria and quick SOFA have 
a significantly greater discrimination for in-hospital mortality (AUROC=0.784 and 0.732, 
respectively) than SIRS (AUROC=0.606;p<0.01 for both). Sepsis-3 had higher incidence of acute-
on-chronic liver failure, septic shock and transfer to ICU than those without Sepsis-3. Similar 
results were observed in the validation cohort. In the third study, 69 patients (35%) were readmitted 
within 30 days from discharge. C-reactive protein (CRP) value at discharge (OR=1.91;p=0.022), 
diagnosis of acute-on-chronic liver failure during the hospital stay (OR=2.48;p=0.008) and the 
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hospitalization in the last 30 days previous to the admission/inclusion in the study 
(OR=1.50;p=0.042) were found to be independent predictors of readmission. CRP at discharge was 
also found to be an independent predictor of 6 month mortality (HR=1.85;p=0.001) as well as age 
(HR=1.05;p=0.001), MELD score (HR=1.13;p<0.001), refractory ascites (HR=2.22;p=0.007) and 
diabetes (HR=2.41;p=0.010). Patients with a CRP>10 mg/l at discharge had a significantly higher 
probability of being readmitted within 30 days (44 vs 24%; p=0.007) and a significantly lower 
probability of 6-month survival (62 vs 88%;p<0.001) than those with a CRP≤10 mg/L 
Conclusions: The first studies allowed to clarify the different epidemiology of bacterial infections 
in different centers suggesting different approach for the empirical treatment. The second study 
suggests that Sepsis-3 criteria and qSOFA are reliable tools to define the severity of infections and 
thus “sepsis” in patients with cirrhosis. Accordingly, an algorithm has been provided for the 
application of these criteria in patients with cirrhosis. Finally, the third study suggest that CRP 
levels may be potentially used to guide the antimicrobial stewardship in patients with cirrhosis and 
bacterial infections. 
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BACKGROUND 
 
Liver cirrhosis results from different mechanisms of liver injury that lead to necroinflammation 
and fibrogenesis[1]. Liver cirrhosis is histologically characterized by marked distortion of the 
liver parenchyma due to large fibrous septa, due to deposition of collagen, that surround 
regeneration nodules of hepatocytes. The alterations in liver architecture impairs the portal vein 
circulation through the liver causing an increase in portal pressure. The parenchymal extinction 
causes an impairment of the liver synthetic function. Prevalence of cirrhosis is of about 1%, 
however, a recent study from England reported that the incidence of cirrhosis has increased by 
51% during a 10-yr period, from 1998 to 2009, for all etiology[2]. Cirrhosis is an increasing 
cause of morbidity and mortality in more developed countries. It is the 14th most common cause 
of death in adults worldwide, but the fourth in central Europe; it results in 1·03 million deaths 
per year worldwide, 170,000 per year in Europe[3]. The natural history of cirrhosis is 
characterized by a phase characterized by the absence of relevant symptoms of the disease 
(compensated cirrhosis) and a phase characterized by the appearance of complications of 
cirrhosis, the main one represented by the appearance of ascites, gastrointestinal bleeding, 
hepatic encephalopathy and or bacterial infections. When decompensation occurs, the 1 year 
survival probability rate decreases to 50%[4]. The most common cause of death in these patients 
is the development of a syndrome characterized by organ failures (kidney, brain, liver, 
coagulation, circulation and lung) named acute-on-chronic liver failure (ACLF)[5], a condition 
that is frequently precipitated by a bacterial infection[5–7] 
 
Prevalence of infections in patients with cirrhosis 
Patients with cirrhosis of the liver have a high risk of bacterial infections[8]. A large study 
performed in the U.S. (175 million hospital discharge) showed that patients with cirrhosis had a 
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risk of sepsis 2.6 fold higher than those without[9]. In addition, the risk of dying due to sepsis 
was 2 fold higher in patients with cirrhosis than those without cirrhosis. More in detail, the 
prevalence of bacterial infections is about 25-46% in patients hospitalized for an acute 
decompensation of cirrhosis[5,10]. In hospitalized patients with cirrhosis, bacterial infections are 
more common in those with ascites than in those without ascites (45 vs 17 %: p<0.001)[10]. 
Spontaneous bacterial peritonitis (SBP) and urinary tract infections (UTI) are the most common 
infections in patients with cirrhosis followed by pneumonia, skin and soft tissue infections and 
spontaneous bacteremia[10–12]. Risk factors for the development of infection are poor liver 
function, variceal bleeding, low ascitic fluid protein levels, and prior SBP[13]. Both infections 
due to gram positive and gram negative bacteria are increased in patients with cirrhosis[9] and 
cirrhosis of the liver is also considered a risk factor for fungal infections.  
 
Pathogenesis of bacterial infections in cirrhosis  
Several factors are involved in the pathogenesis of bacterial infections in patients with cirrhosis. 
In patients with SBP and spontaneous bacteremia, the conditio sine qua non is a pathological 
bacterial translocation from the intestinal lumen to mesenteric lymph node. The pathological 
bacterial translocation is related to several factors, including: quantity and quality of intestinal 
bacteria, increased intestinal permeability and local defects in host immunity[14]. The occurrence 
of the other infections, as well as SBP is facilitated due to a cirrhosis associated immune 
dysfunction[15] 
 
Genetic predisposition 
Extracellular bacteria are recognized by membrane-bound of pattern recognition receptors 
(PRRs) such as Toll-like receptors (TLR) and intracellular Nod-like receptors (NLR), including 
NOD2 and NLRP3, which lead to activation of nuclear factor NFKb and stimulate the release of 
antimicrobial peptides[8]. TLR2 recognizes tri-acylated lipoprotein from gram-positive bacteria, 
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TLR4 detects lipopolysaccharide (LPS), and NOD2 senses muramyl dipeptide, a cell wall 
component of gram-negative bacteria. 
Genetic polymorphisms NOD2 and TLR2, have been associated with the onset of SBP[16,17]. 
The presence of the nucleotide-binding oligomerization domain containing 2 (NOD2) variants 
p.R702W, p.G908R, and c.3020insC increased the risk of SBP 3 fold, probably due to an 
increased intestinal permeability[16].  
SBP was significantly more frequent in patients with the TLR2 -16934 TT genotype  and in 
carriers with two long tandem GT repeat alleles[17]. Furthermore, the simultaneous presence of 
NOD2 and TLR2 polymorphisms indicated a particularly high risk for SBP [17]. 
 
Intestinal bacterial overgrowth 
The intestinal bacterial overgrowth plays a key role in BT in cirrhosis and is the result, at least 
partly, of decrease in small-bowel motility and the delayed intestinal transit existing in these 
patients [18,19]. It has been suggested that autonomic dysfunction, increased NO synthesis and 
the oxidative stress of the mucosa are the main causes for decreased intestinal motility 
 
Intestinal bacteria quality 
The full microbial richness in the human population reaches up to 40,000 species [20]. However, 
only 30–40 species amount to about 98–99% of the microbiota, and Firmicutes and Bacteroidetes 
are the predominant intestinal phyla across all vertebrates[21]. The microbiota of cirrhosis has 
been associated with the depletion of the beneficial phyla Lachnospiraceae (particularly 
clostridiae) and enrichment in the phyla Proteobacteria (mainly Enterobacteriaceae) and 
enterococceae[22–24]. Gram-negative bacteria (GNB) (specifically E. coli, K. pneumoniae, P. 
aeruginosa and other Enterobacteriaceae), enterococci and other streptococci, have been found to 
be the most adept at translocating to MLN[25]. Interestingly, these species and among those 
particularly E. coli are those that most frequently cause spontaneous bacterial infections in 
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cirrhotic patients[11,26]. Recently Bajaj JS and coll. found that the ratio between “good” vs 
“bad” species (cirrhosis dysbiosis ratio) was reduced in hospitalized patients with cirrhosis and 
infection and was negatively correlated with endotoxemia (r = -0.4, p = 0.002)[24]. 
 
Intestinal permeability 
Intestinal mucosal barrier represents a physical and biological hurdle to bacterial traslocation. 
The mucins, the secretory mucosal Immunoglobulin A antibodies, alfa-defensins, lysozyme and 
the tight junctions protect the epithelium against local and systemic bacterial invasion[14]. 
 An increased intestinal permeability (IP) was found in cirrhotic patients compared with healthy 
controls[27]. Furthermore, a significant correlation between the increased IP and the severity of 
the liver disease and history of SBP was found. Several factors increase IP in cirrhosis, ultra-
structural changing of intestinal mucosa such as widening of intracellular spaces, vascular 
congestion, edema of the lamina propria, fibromuscular proliferation, a decreased villous/crypt 
ratio, wall thickening and tight junctions disruption was previously reported[28]. Oxidative stress 
of intestinal mucosa increases lipid peroxidation and glycosylation of the brush border 
membranes and mucins[29]. Inflammatory pathway also appears to affect IP. In experimental 
cirrhosis, the over production of tumor necrosis factor-alpha (TNF-alpha), also described in 
cirrhotic patients, alters the structure of the intestinal mucosa, decreasing expression of tight 
junctions (zona occludens 1; ZO-1)[30] and increasing IP. Interstingly, anti-TNF monoclonal 
antibody as well as pentoxifylline treatment significantly decreases bacterial translocation in 
experimental cirrhosis[31]. Finally, the hyperactivity of the autonomic nervous system has been 
associated with alteration in IP. In cirrhotic ascitic rats splanchnic specific sympathectomy has 
been shown to prevent translocation and spreading of E. coli, being associated with increased 
chemotaxis and phagocytic capacity of mononuclear cells[32]. Additional proposed beneficial 
effects of sympathectomy are accelerated intestinal transit time, prevention of gram-negative 
bacteria overgrowth and improvement in gastrointestinal permeability[14]. Propranolol has 
 8 
 
likewise been used and found to lower incidence of SBP in cirrhotic patients[33]. 
 
Host immunity in cirrhosis 
Cirrhosis is associated with several abnormalities in innate and adaptive components of the 
immune system’s response to microbial challenge, leading to a state of acquired 
immunodeficiency[15].  
The impairment of liver function causes a reduction in the synthesis of innate immunity proteins 
such as complement, reducing the bactericidal capacity of phagocytic cells[34].  
The overall number of leukocytes is frequently reduced in stable patients with cirrhosis, due to 
hypersplenism. In addition, a reduction of bone marrow stem cells niche has been recently 
reported and may contribute to the reduced circulating leukocytes[35].  
Among immune cells involved in innate immunity, neutrophils are reduced in numbers and 
shows a reduced phagocytosis of opsonized bacteria[36–38]. The reduction of intracellular 
killing is due to defective superoxide anion O2– production and myeloperoxidase activity[36]. 
These alterations seem to involve intracellular signaling mechanisms[36–38]. Neutrophils also 
show impaired chemotaxis to the infection focus. Moving to monocytes, they are markedly 
increased in number and present an over expression of the TLRs[39] with an over production of 
TNF-alpha[40] in patients with cirrhosis. However, monocytes shows a in Fc gamma-receptors 
function[41] that has been linked to a risk of developing bacterial infections. In addition, in 
patients with acute decompensation of cirrhosis shows an overproduction of the cyclooxygenase-
derived eicosanoid prostaglandin E2[42]. In vitro administration of plasma from patients with 
acute decompensation of cirrhosis to healthy monocytes caused a suppression of macrophage 
proinflammatory cytokine secretion and bacterial killing, that was restored by PGE2 receptor 
antagonists[42]. Interestingly, the administration of albumin, which reduces PGE2 
bioavailability, improved the macrophage proinflammatory response to LPS[42]. Finally, in the 
most severe patients with cirrhosis, namely those with ACLF, monocytes showed an 
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overexpression of MERTK receptors that mediates a blunted inflammatory response to LPS 
stimulation[43]. In addition, in patients with ACLF an increase in mononuclear myeloid-derived 
suppressor cells was shown, that decreased T cell proliferation, produced less TNF-alpha in 
response to TLR stimulation, and reduced bacterial uptake of Escherichia coli[44]. Interestingly,  
it has been shown that patients with ACLF have a very high short-term occurrence of bacterial 
and fungal infections[7] 
Among immune cells mostly involved in acquired immunity, both B and T lymphocytes are 
reduced in number and show an impairment in immune function. The most striking anomaly 
observed in the B cell compartment is memory B cell dysfunction. Specifically, cirrhosis leads to 
a loss of CD27+ memory B cells causing an hypo-responsiveness to CD40/TLR9 
activation[45].T cell depletion is due to an impairment in the production of new naive T cells due 
to accelerated aging and atrophy of the thymus, reduction of the T cell memory subset, due to 
spleen sequestration and cell consumption, and impaired compensatory peripheral 
proliferation[15,46]. 
 
Clinical impact of bacterial/fungal infections in cirrhosis 
Bacterial infections are a common cause of decompensation in patients with cirrhosis[5]. 
Specific bacterial components such as LPS from gram negative bacteria or tri-acylated 
lipoprotein from gram-positive bacteria (also called pathogens associated molecular patterns 
[PAMPs]) are recognized by PRRs on immune cells, causing the release of proinflammatory 
mediators. Thus, bacterial infections may cause a status of exaggerated systemic inflammation in 
patients with cirrhosis[47]. This inflammation can be responsible of tissue damage and organ 
failure[48]. Interestingly, according to a new hypothesis, systemic inflammation is the main 
driver of decompensation, organ failures and ACLF in patients with cirrhosis[49]. In fact several 
lines of evidence suggests that PAMPs may exacerbate splanchnic arterial vasodilation; reduce 
cardiac contractility; induce renal dysfunction and brain edema[49]. Therefore, bacterial 
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infections may frequently cause acute kidney injury (AKI) and are the most common precipitants 
of hepatorenal syndrome (HRS)[10,50,51]. In addition, a cognitive impairment with clinical 
characteristics of hepatic encephalopathy is frequently caused by bacterial infections[52]. Thus, it 
is not surprising that bacterial infections are the most common trigger of ACLF[5]. Finally, 
bacterial infections increase 4 fold the risk of mortality in patients with cirrhosis, reaching 30% 
at 1 month and 63% at 1-year[53]. 
 
Diagnosis of bacterial infections in cirrhosis 
Signs and symptoms of infections may be very subtle in patients with cirrhosis, thus in all 
patients hospitalized for an acute decompensation of cirrhosis the presence of infections should 
be investigated. Systemic inflammatory response syndrome (SIRS) criteria (at least 2 among 
body temperature<36°C or >38°C; heart rate>90 bpm, respiratory rate>20/min, white blood cells 
[WBC]<4.000/µL or>12.000/µL or immature neutrophils>10%) may increase the suspicion of 
infection[13], however, the application of these criteria is problematic in patients with cirrhosis. 
Indeed, patients with cirrhosis may have: a) leukopenia due to hypersplenism, b) tachypnea due 
to hepatic encephalopathy or ascites, c) bradycardia due to the use of beta-blockers[8,13]. Thus, 
SIRS criteria are neither specific nor sensitive in the diagnosis of infections in patients with 
cirrhosis although they can still identify patients at higher risk of in-hospital mortality[54].  
Acute phase protein, such as C-reactive protein (CRP) and procalcitonin (PCT) are widely used 
in general population to diagnose bacterial infections[55,56]. CRP is mainly produced by the 
hepatocytes in response to inflammatory mediators while PCT is produced by several cells. In 
spite of some concerns about the use of CRP as a biomarker of bacterial infections in patients 
with advanced cirrhosis, it was proven to be very accurate, with AUC ranging from 0.64 to 
0.93[57–59]. Sensitivity and specificity of a threshold of CRP of 10 mg/L was 84% and 91%, 
respectively[57]. The diagnostic accuracy of PCT seems to be good in the cirrhotic population, 
similar to those of CRP[57]. The cut-off value proposed for PCT in cirrhosis is identical to that 
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used in the general population, 0.5 ng/ml[13]. The usefulness of CRP and PCT in the stewardship 
of antibiotic treatment needs further investigation in cirrhosis. 
Diagnostic criteria for bacterial infections in patients with cirrhosis are similar to those used in 
the general population. Anyway, some specific spontaneous infections occurring in patients with 
cirrhosis, namely SBP, spontaneous empyema and spontaneous bacteremia deserve a more 
detailed description. SBP is defined as a bacterial infection of ascitic fluid developed in patient 
without any intra-abdominal, surgically treatable source of infection[60]. The diagnosis of SBP is 
based on a polymorphonucear (PMN) cells in ascitic fluid above 250 cells/µl [60].  In patients 
with haemorrhagic ascites with a fluid red blood cell count > 10 000/µl (due to concomitant 
malignancy or traumatic tap), a correction factor of 1 neutrophil per 250 red blood cells (RBC) 
has been proposed, since this is the maximum expected ratio of neutrophils to RBCs normally 
present in peripheral blood[60]. The vast majority of cirrhotic patients with ascites and peritoneal 
infection have SBP. However, a small group of patients have bacterial peritonitis secondary to 
perforation or acute inflammation of intra-abdominal organs, abdominal wall infections or 
previous abdominal surgical procedures[61].  
The differentiation is important because secondary peritonitis usually does not resolve unless 
patients are treated surgically. Secondary peritonitis should be suspected when at least one of the 
following features is present[62]:  a) reduction in ascitic fluid neutrophil count of less than 25% 
(or even an increase) of the pretreatment value after two days of antibiotic treatment; b) More 
than one organism isolated from ascites, strongly suggestive of perforated bowel (particularly 
when the growth of anaerobic bacteria or fungi is observed); c) Runyon’s criteria, represented by 
neutrocytic ascites with at least two of three criteria: ascitic fluid total protein >1 g/dl (in contrast 
to SBP which selectively occurs in low-protein ascites), glucose <50 mg/dl (due to bacterial 
glucose utilization), or LDH >225 mU/ml (most likely due to more rapid metabolic rate and 
disintegration of ascitic PMN)[62].  
These criteria are to be very sensitive in the detection of secondary peritonitis, although their 
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specificity is low. In clinical practice to distinguish ‘secondary peritonitis’ from SBP, patients 
should undergo appropriate radiological investigation like chest X ray and abdominal computed 
tomography scan[61].  
Spontaneous empyema is a spontaneous infection of the pleural fluid and is diagnosed when 
PMN count in pleural fluid is above 250 cells/µL. Finally, spontaneous bacteremia is defined by 
the presence of positive blood cultures with no apparent cause of bacteremia[13].  
 
Antibiotic resistance in cirrhosis 
In recent years there has been concern about the increasing isolation of bacteria resistant to 
common antibiotics used in these patients. Observational studies coming from 
Europe[11,26,63,64], North America[12,65] and Asia[66] showed a high rate of infections due to 
multi-drug resistant (MDR) bacteria (bacteria resistant to to 3 or more of the main antibiotic 
families) in patients with cirrhosis.  
The most common MDR bacteria isolated in patients with cirrhosis are estended spectrum beta 
lactamase (ESBL) producing Enterobacteriaceae, methicillin resistant Staphylococcus Aureus 
(MRSA) and Enterococcus Faecium[11,26,65,67]. In addition, the appearance of extensively 
resistant (XDR) bacteria (bacteria resistant to at least one antibiotic in all classes excepting 2) 
such as carbapenemase producing Klebsiella Pneumoniae has been recently reported[68,69].  
The site of acquisition of infection determines the risk of MR bacterial infection with higher rates 
of MR bacteria in infections acquired in the healthcare environment: 23–39% in nosocomial 
infections, 14-41% in healthcare-associated (HCA) episodes and 0–16% in infections acquired in 
the community[11,13,64]. Other risk factors correlated with MDR bacteria were norfloxacin 
prophylaxis, use of beta lactams in the previous 3 months and infection due to MDR in the 
previous 6 months[11,26,65].  
 13 
 
According to the above mentioned epidemiological changes, the efficacy of 3rd  generation 
cephalosporins as well as alternative therapies such as amoxicillin-clavulanic acid or quinolones 
has decreased[11,26,63–67,70–72]. Indeed, MDR infections are more difficult to be treated and 
frequently the empirical antibiotic treatment is ineffective in these infections [8,11]. As a 
consequence incidence of septic shock and mortality rate is significantly higher in patients with 
MDR bacterial infections [11,73].  
Thus, there is the urgent need to develop new strategies in the prevention and treatment of 
bacterial infections in patients with cirrhosis. However, in this field, large epidemiological 
studies are lacking and/or limited to single center experiences. As a result, a global view of the 
epidemiology of bacterial infections across the world is currently missing. 
 
 
Treatment of infections in patient with cirrhosis 
General management 
Blood urine and ascites cultures should be collected at the diagnosis of infections, before the 
administration of antibiotics. Vital signs (body temperature, arterial blood pressure, respiratory 
rate, heart rate and oxygen saturation, cognitive status etc) should be checked. In hypotensive 
patients, resuscitation fluid should be administered as soon as possible. The assessment of renal 
and liver function tests should be performed to diagnose AKI or ACLF. Patients with AKI should 
be managed according to the current Internationa Club of Ascites recommendations[74]. Patients 
with severe sepsis or septic shock should be treated with a early goal directed therapy[13,75] 
 
Antibiotic treatment 
Empirical antibiotic treatment should be initiated as soon as possible after the diagnosis of a 
bacterial infection[8,13]. This statement is due to the demonstration that any delay in the 
administration of an effective antibiotic treatment is associated with an increased risk of 
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mortality in patients with cirrhosis and septic shock[76]. The administration of an effective 
antibiotic treatment is critical to improve the outcomes of patients with cirrhosis and bacterial 
infections. Indeed, several studies have shown that the inefficacy of empirical antibiotic 
treatment is the strongest predictor of short-term mortality in patients with cirrhosis and bacterial 
infections[26,67,70,72]. The decision of the empirical antibiotic treatment should be guided by 
the following considerations: a) type of infection; b) risk of a multi drug resistant (MDR) 
bacterial infection (health care associated [HCA] or nosocomial, recent exposure to systemic 
antibiotics; norfloxacin prophylaxis etc.) and c) the severity of infection and d) local 
epidemiology[8]. Ideally, the empirical treatment should cover all potential organisms 
responsible for infection, but should consider also the potential side effects and the need to spare 
antibiotics active against MDR bacteria (carbapenems, glycopeptides etc.)[13]. In Table 1 the 
current recommended empirical antibiotic treatment has been reported[8].  
In community acquired infections, third generation cephalosporins are considered safe and 
effective for treating SBP, spontaneous bacterial empyema and spontaneous bacteremia. 
Amoxicillin/clavulanic acid is a good alternative to 3rd generation cephalosporins in patients with 
spontaneous infections. Community acquired UTI should be treated with quinolones or 
cotrimoxazole in patients without complication and in center with a low prevalence of quinolone 
resistant Enterobacteriaceae. Patients with complicated UTI should be treated with 3rd generation 
cephalosporins or amoxicillin/clavulanic acid. The treatment of community acquired pneumonia 
should include the combination of 3rd generation cephalosporins or amoxicillin/clavulanic acid 
plus macrolides. An alternative strategy is the administration of monotherapy with respiratory 
quinolones. The treatment suggested for community acquired skin and soft tissues infections 
(SSTIs) is the combination of 3rd generation cephalosporins or amoxicillin/clavulanic acid plus 
oxacillin. The antibiotic regimen suggested for uncomplicated HCA and nosocomial UTI is the 
use of piperacillin/tazobactam (in center with a low prevalence of MDR bacteria) or 
carbapenems. The addition of glycopeptides (vancomycin or teicoplanin) may be suggested in 
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centers with high prevalence of methicillin resistant Staphylococcus Aureus (MRSA) or 
vancomycin sensitive enterococci (VSE). Linezolid is suggested in centers with high prevalence 
of vancomycin resistant enterocci (VRE). 
 
Table 1: Recommended empirical antibiotic treatment for community-acquired and 
nosocomial bacterial infections in cirrhosis (modified from Jalan R et al ref.8) 
Type of infection Community-acquired infections Nosocomial infections* 
SBP, spontaneous bacterial 
empyema and spontaneous 
bacteremia 
Cefotaxime 
or ceftriaxone 
or amoxicillin/clavulanic acid 
Piperacillin/tazobactamΔ 
or meropenem§ ± glycopeptide# 
UTI 
Uncomplicated: 
Ciprofloxacin 
or cotrimoxazole 
 
If sepsis: 
cefotaxime 
or ceftriaxone 
or amoxicillin/clavulanic acid 
Uncomplicated: 
nitrofurantoin or fosfomycin 
 
 
If sepsis: 
piperacillin/tazobactam° 
or meropenem ± glycopeptide# 
 
Pneumonia 
Amoxicillin/clavulanic acid 
or ceftriaxone + macrolide 
or levofloxacin 
or moxifloxacin 
Piperacillin/tazobactam ° 
or meropenem/ceftazidime + 
ciprofloxacin ± 
glycopeptide# should be added 
in patients with risk 
factors for MRSA§ 
Cellulitis Amoxicillin/clavulanic acid 
or ceftriaxone + oxacillin 
Meropenem/ceftazidime + 
oxacillin 
or glycopeptides# 
Legend: SBP, spontaneous bacterial peritonitis; SBE, spontaneous bacterial empyema; MRSA, 
methicillin-resistant Staphylococcus Aureus.  
*, Recommended empirical treatment also for health-care associate (HCA) urinary infections and 
pneumonia. Empirical antibiotic treatment of HCA spontaneous infections and cellulitis will be 
decided on the basis of the severity of infection (patients with severe sepsis should receive the 
schedule proposed for nosocomial infections) and on the local prevalence of multiresistant 
bacteria in HCA infections. 
°, In areas with a low prevalence of multi drug resistant bacteria. 
#, IV vancomycin or teicoplanin in areas with a high prevalence MRSA and vancomycin-
susceptible enterococci. Glycopeptides must be replaced by linezolid in areas with a high 
prevalence of vancomycin-resistant enterococci. 
§, Ventilator-associated pneumonia, previous antibiotic therapy, nasal MRSA carriage 
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In patients with nosocomial spontaneous infections (SBP, spontaneous bacterial empyema and 
spontaneous bacteremia), the treatment suggested is piperacillin/tazobactam (in center with a low 
prevalence of MDR bacteria) or carbapenems are suggested. The addition of glycopeptides 
should be reserved to centers with a high prevalence of MRSA and VSE.  Interestingly, a 
randomized controlled trial, in a center with a high prevalence of extendend spectrum beta 
lactamases (ESBL) enterobateriaceae, MRSA and enterococci, the combination of meropenem 
plus daptomycin showed to be more effective than ceftazidime in the treatment of nosocomial 
SBP[67]. In addition, the administration of an effective empirical treatment was found to be an 
independent predictor of survival. The treatment suggested for HCA infections should be titrated 
according to the local epidemiology (broad spectrum for centers with high prevalence of MDR 
bacteria and those provided for community acquired infections in centers with a low prevalence 
of MDR). In a randomized controlled trial, comparing a broad spectrum antibiotic treatment 
versus standard treatment, in patients with cirrhosis and HCA infections, the broad spectrum 
treatment was more effective and associated with a lower mortality than standard treatment[70].  
The treatment suggested for HCA or nosocomial pneumonia includes piperacillin/tazobactam (in 
center with a low prevalence of MDR bacteria) or carbapenems plus a respiratory quinolone. The 
addition of glycopeptides should be reserved to centers with a high prevalence of MRSA. 
Linezolid is suggested in centers with high prevalence of vancomycin resistant enterocci (VRE). 
Nosocomial SSTIs should be treated with carbapenems or ceftazidime plus oxacillin, while 
glycopeptides can be added in centers with a high prevalence of MRSA. The treatment of other 
infections should follow international guidelines. Aminoglycosides use should be avoided in 
patients with cirrhosis because it is associated with a high risk of AKI[77]. If microbiological 
cultures allows the identification of the strain responsible for the infection, the antibiotic regimen 
should be narrowed according to the antibiotic susceptibility test, to decrease the likelihood of 
emergence of antibiotic resistance[8,13].  
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Prevention of acute kidney injury (AKI) 
Patients with bacterial infections and in particular SBP, have a high risk to develop AKI. Thus, 
they represent optimal candidates for the development of strategies aimed to prevent the 
development of AKI. A randomized controlled clinical trial showed that the administration of 
antibiotics + albumin (1.5 g per kg of body weight on day 1 and 1 g per kg of body weight on day 
3) in patients with SBP is associated with a lower risk to develop HRS than antibiotic alone[78]. 
Furthermore, mortality rate was significantly lower in patients treated with albumin than in those 
treated with standard of care[78].  
In patients with bacterial infections other than SBP results are controversial. Guevara M et al 
found a significant improvement in renal function and a trend towards an improvement in 
survival with the administration of albumin[79]. On the contrary, Thevenot T et al. found 
albumin able to delay the onset of renal failure, although the three-month renal failure rate and 
survival rate were not different between the two groups[80]. Importantly, they reported 8 cases of 
pulmonary edema in patients treated with albumin.  
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RATIONALE OF THE STUDIES 
As mentioned in the background section, bacterial infections in cirrhosis are common, are 
associated with the development of complications of cirrhosis and confer a high mortality rate. 
Thus, any effort should be mad to improve the management of patients with cirrhosis and 
bacterial infection. It should be highlighted that in the eighties and nineties, the management of 
infections in cirrhosis has been significantly improved. In fact, a recent meta-analysis of studies 
including patients with cirrhosis and bacterial infections reported a reduced 30-day mortality in 
studies performed between 2000 to 2009 than in those performed between 1978 to 1999 (26 vs 
37%; P= 0.01)[53]. However, thereafter, mortality for bacterial infections raised up. In fact, a 
retrospective analysis of 781,515 hospitalization from 2002 through 2010 in the U.S. showed that 
the risk of dying for a cirrhosis patient with sepsis was 28% higher in 2010 than in 2002[81]. 
Remarkably, this finding was in contrast with the observation that the risk of dying for several 
other complications of cirrhosis such as HRS GI bleeding or hepatocellular carcinoma 
significantly decreased overtime[81] (Figure 1). 
Figure 1. Incident risk ratios of in-hospital mortality for cirrhosis complications, each year 
from 2002 to 2010. 
 
Legend: HRS, hepatorenal syndrome; GI, gastrointestinal; *, p<0.01 vs 2002. Modified from 
ref.81. 
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This findings are alarming and occurred despite the ongoing “surviving sepsis campaign”[82]. 
The reasons are not clear, but the increase in the spread of MDR bacteria and the lack of new 
effective antibiotics may be one. The problem of antimicrobial resistance is so important that on 
September 2016 the United Nations hold a meeting on this topic that resulted in a declaration of 
actions to counteract the spread of MDR strains[83]. As reported before, there is the urgent need 
to develop new strategies in the prevention and treatment of bacterial infections in patients with 
cirrhosis. In our mind, the first step to be done was to perform large epidemiological studies to 
understand better the epidemiology of infections across the world. Thus, we performed a 
multicenter, prospective intercontinental study to evaluate epidemiology and clinical impact of 
bacterial/fungal infections across the world (Study 1). Another important step is to identify 
patients with cirrhosis at high risk of short term mortality that deserve a more intensive 
management and could be the target of trials of intervention. The current definition of sepsis, 
according to the presence of SIRS criteria has several limitations in cirrhosis. Thus, we evaluated 
for the first time the new consensus definitions of the Society of Critical Care Medicine and the 
European Society of Intensive Care Medicine (Sepsis-3 criteria)[84], in patients with cirrhosis 
and bacterial/fungal infections comparing the new criteria with the SIRS criteria(Study 2). 
Finally, for patients discharged after a hospitalization for bacterial infections there is a high rate 
of short term readmission[85,86]. Thus, we conducted a study assessing predictors of early 
readmissions and mid-term mortality in patients with cirrhosis and bacterial infections after the 
discharge (Study 3). The results of Study 2 and Study 3 have been recently published [87,88]. 
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STUDY 1:  
EPIDEMIOLOGY AND CLINICAL IMPACT OF BACTERIAL 
INFECTIONS IN PATIENTS WITH CIRRHOSIS ACROSS THE WORLD: 
THE “GLOBAL STUDY” 
 
Introduction 
In recent years there has been concern about the increasing isolation of bacteria resistant to 
common antibiotics used in patients with cirrhosis and bacterial infections. Observational studies 
coming from Europe[11,26,63,64], North America[12,65] and Asia[66] showed a high rate of 
infections due to MDR bacteria in patients with cirrhosis.  
Furthermore, XDR bacteria such as carbapenemase producing Klebsiella Pneumoniae, 
Acinetobacter Baumannii etc. are becoming a relevant issue for the management of these 
patients[68,69].  
Norfloxacin prophylaxis for SBP, the use of antibiotics in the 3 months before on set of infection 
and nosocomial acquisition of infections has been found to be associated with a high risk of 
infections due to multi drug resistant bacteria[11,13,26,64,65]. 
These epidemiological studies highlight the urgent need to develop new strategies in the 
prevention and treatment of bacterial infections in patients with cirrhosis. However, in this field, 
large epidemiological studies are lacking and/or limited to single center experiences. Thus, they 
are not fully able to give a global view of the epidemiology of bacterial infections across the 
world. 
A large multi-center international observational study may be helpful to better understand the 
epidemiology of bacterial infections and the pattern of antibiotic resistance in patients with 
cirrhosis in the different countries. It may also be helpful in the selection of empirical antibiotic 
treatment in these patients. This is a critical point, since in cirrhotics with bacterial infections, an 
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inappropriate empirical antibiotic treatment of SBP has been associated with a poor 
survival[26,67,70] and with severe sepsis or septic shock[76]. For these reasons a consensus 
among international experts was held to suggest new guidelines on the antibiotic treatment of 
bacterial infections in patients with cirrhosis[8]. Nevertheless, the Authors highlight the need to 
base the antibiotic treatment on the local pattern of antibiotic resistance. For these reasons an 
international survey including centers coming from all the continents may be useful to better 
define antibiotic treatment in these patients. Thus, on 2014, the International Club of Ascites, 
planned a prospective, cross sectional, multicenter, intercontinental study to investigate the 
epidemiology and pattern of antibiotic resistance, as well as the clinical impact of bacterial 
infections in patients with cirrhosis. The study had the acronym “Global study” 
 
Materials and methods 
Patients 
From October 2015 to October 2016 consecutive patients with cirrhosis and bacterial infections 
were included at 46 centers (15 from Asia, 15 from Europe, 11 from Southern America and 5 
from Northern America). Inclusion criteria were the following: a) diagnosis of cirrhosis 
according to histological, clinical, biochemical, ultrasound and/or endoscopic findings; b) 
diagnosis of bacterial and/or fungal infection during hospitalization; c) age>18 years old. 
Exclusion criteria were: a) hepatocellular carcinoma (HCC) beyond the Milan criteria; b) 
extrahepatic malignancy; c) severe extrahepatic disease (congestive heart failure stage NYHA≥3, 
chronic obstructive pulmonary disease stage GOLD≥3; chronic kidney disease requiring renal 
replacement therapy[RRT]); d) previous transplant; e) HIV infection; f) use of 
immunosuppressive drugs other than corticosteroids for the treatment of severe acute alcoholic 
hepatitis; g) inability to provide written informed consent.  
The protocol was approved by the local Ethics Committee at each center and all patients 
provided written informed consent. 
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Design of the study 
Once informed consent was obtained, a physical examination, routine laboratory and 
microbiological analyses were performed. Demographic, clinical, laboratory and microbiological 
data, as well as treatment administered were collected. Information about concurrent medications 
(quinolones prophylaxis, rifaximin and beta-blockers) were collected as well. The following 
potential risk factors for the development of MDR and XDR infections were collected: i) 
antibiotic treatment for at least 5 days in the previous 3 months; ii) Isolation of MDR bacteria in 
the previous 6 months; iii) invasive procedures (surgery, central venous catheterization, bladder 
catheterization, paracentesis etc.) in the month before the hospitalization. 
Bacterial/fungal infections were classified as community acquired (CA), health-care associated 
(HCA) and nosocomial infections as previously shown[11]. Bacterial/fungal infections were 
diagnosed according to the following conventional criteria: 
- Spontaneous bacterial peritonitis (SBP): polymorphonuclear cell count in ascitic fluid ≥ 
250/mm3 [60] 
- Urinary trait infections (UTI): Patient had at least one of the following signs or symptoms 
(fever ≥ 38° C, urgency, frequency, dysuria, or suprapubic tenderness) and a positive 
urine culture or at least two of the following signs or symptoms (fever ≥ 38° C, urgency, 
frequency, dysuria, or suprapubic tenderness) and at least one of the following (more than 
10 leukocytes/µL in urine)[89]. 
- Pneumonia: radiologic evidence of a new, or progression of a previous, pulmonary 
infiltrate, consolidation or cavitation  plus at least one of the following criteria ( fever ≥ 
38ºC, leucocyte count of >12,000/mm3 or <4,000/mm3) plus at least one of the following 
symptoms (new onset of purulent sputum or change in character of sputum, new onset of 
cough, dyspnea or tachypnea >20 breaths per minute, rales or bronchial breath sounds or 
worsening of gas exchange) and/or organisms cultured from blood, pleural fluid or a 
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specimen obtained by transtracheal, aspirate, bronchoalveolar lavage, or biopsy 
- Spontaneous bacteremia: at least 1 of the following signs or symptoms: fever (≥ 38°C), 
chills, or hypotension and a positive blood culture (at least two positive blood cultures for 
common skin contaminant), in the absence of a known source of infection [2] 
- Other infections were diagnosed according to the Centers for Disease Control and 
Prevention Criteria[89]. 
Microbiological cultures and antibiotic susceptibility tests, were performed according to standard 
international criteria. Patients were followed-up until death, liver transplantation (LT) and/or 
discharge. Patients discharged before 28 days were followed up until 28 days since the diagnosis 
of infection. Data on the development of new bacterial/fungal infections, septic shock, AKI, 
ACLF, the transfer to the ICU, the use of vasopressors, mechanical ventilation and/or RRT 
during the hospitalization were collected. Microbiological data about second infections during 
the hospitalization were collected. Data were collected using an electronic case report form using 
the Research Electronic Data Capture Software REDCap[90] hosted at the Department of 
Medicine – DIMED of the University of Padova, Italy  
 
Definitions 
MDR bacteria were defined as bacteria resistant at least one antibiotic in 3 or more classes[91]. 
XDR bacteria were defined as bacteria resistant to at least one antibiotic in all classes excepting 
2[91]. For the assessment of MDR and XDR definitions intrinsic resistance were not considered 
(e.g. Enterococci are constitutively resistant to cephalosporins). 
ACLF was defined according to the EASL-CLIF consortium definition in patients developing an 
acute decompensation of cirrhosis[5]: Grade 1: Patients with serum creatinine (SCr) ≥ 2 mg/dl; 
patients with single failure of the liver, coagulation, circulation, or respiration who had a SCr 
level ranging from 1.5 to 1.9 mg/dL and/or mild to moderate hepatic encephalopathy (grade 1 or 
2 according to West Haven criteria); and patients with single cerebral failure who had a SCr level 
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ranging from 1.5 to 1.9 mg/dL; Grade 2: Patients with 2 organ failures; Grade 3: Patients with 3 
or more organ failures. 
AKI was defined as an increase in SCr ≥ 0.3 mg/dL with respect to baseline according to 
International Club of Ascites criteria [5]. AKI stages were defined as follows: Stage 1: increase 
in SCr ≥ 0.3 mg/dL (26.5 mmol/L) or an increase in 1.5-fold to 2-fold from baseline; Stage 2: 
increase in SCr between 2-fold and 3-fold from baseline; Stage 3: increase of SCr >3-fold from 
baseline or SCr ≥ 4.0 mg/dL with an acute increase ≥ 0.3 mg/dL or initiation of renal-
replacement therapy. 
Efficacy of first line antibiotic treatment was defined by each investigator according to clinical 
improvement and microbiological tests.  
For the assessment of microbiological efficacy of currently suggested recommendations for the 
treatment of infections in patients with cirrhosis (Table 1 - Background) [8] we considered 
recommendations adequate if the isolated strain was sensitive to at least one of the antibiotic 
suggested. We differentiated the antibiotic strategy suggested for HCA and nosocomial infections 
as follows: a) treatment suggested including carbapenems; b) treatment suggested including 
piperacillin/tazobactam and no carbapenems (for spontaneous infections, UTI and pneumonia); 
c) treatment suggested including carbapenems and glycopeptides/ oxazolinidones). 
 
Management of infections 
The empirical antibiotic treatment was administered according to local protocols and changed 
according to antibiotic susceptibility test and clinical evolution. Patients with septic shock 
received resuscitation with plasma expanders and vasopressors. The decision to transfer patient 
to the intensive care unit and to administer mechanical ventilation and RRT was made by the 
physician in charge for the patient according to clinical conditions and standard 
recommendations [75,92]. 
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Statistical analysis 
The primary end point of the study was the presence of MDR and XDR infections. Secondary 
end-points were in-hospital mortality, 28-day mortality, development of ACLF, septic shock, 
transfer to the ICU, and need for organ support (mechanical ventilation or RRT) during the 
hospitalization. Continuous variables were reported as mean ± standard deviation or median with 
interquartile range (IQR) according to normal or non-normal distribution, respectively. They 
were compared using Student's T-test or Mann-Whitney U test, respectively. Categorical 
variables were reported as proportions and compared with chi-square or Fisher’s exact test. 
Variables found to be associated with MDR and XDR bacteria with a p-value<0.1 in the 
univariate analysis were included in a multivariate step-wise logistic regression analysis, with 
backward elimination (entry p<0.05; drop p>0.1). The odds ratios (OR) and their 95% CI were 
calculated. A similar approach was used to identify predictors of in-hospital mortality. When 
scores of liver disease were included in the model, their component were excluded to avoid 
multicollinearity. Similarly, in case of a correlation>0.5 between variables and or scores, they 
were not included in the model to avoid multicollinearity. Non-normally distributed continuous 
variables were log-transformed to be included in the multivariate models. All statistical tests 
were two-tailed and P-values<0.05 were considered significant. The statistical analysis was 
performed using SPSS statistical package, and SAS version 9.4. 
 
Results 
Study population 
During the study period 1,302 patients were enrolled, 565 (43%) from Europe, 416 (32) from 
Asia and 321 (25%) from South and North America. Demographic and clinical characteristics of 
patients included in the study have been reported in Table 1.1 
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Table 1.1. Characteristics of patients included in the study 
Variable N= 1,302 
Continent – n (%) 
   Asia 
   America 
   Europe 
 
416 (32) 
321 (25) 
565 (43) 
Geographic area – n (%) 
   India 
   Other Asian centers 
   North Europe 
   South Europe 
   North America 
   South America 
 
250 (19) 
166 (13) 
137 (11) 
428 (33) 
69 (5) 
252 (19) 
Age (years) – mean (SD) 57 (13) 
Gender (Male) – n (%) 898 (69) 
Etiology – n (%) * 
  HBV 
  HCV  
  Alcohol  
  NASH 
  Other 
 
100 (8) 
259 (20) 
697 (54) 
146 (11) 
236 (18) 
Mean arterial pressure (mmHg) – mean (SD) 82 (13) 
Heart rate (bpm) – mean (SD) 88 (17) 
Body temperature (°C) – mean (SD)  37 (1) 
Respiratory rate (breath/min) – mean (SD) 19 (5) 
Beta-blockers use – n (%) 423 (33) 
Ascites – n (%) 1,002 (77) 
Hepatic encephalopathy – n (%) 496 (38) 
ACLF – n (%) 460 (35) 
ACLF grade – n (%) 
   Grade 1 
   Grade 2 
   Grade 3 
 
190 (15) 
164 (13) 
106 (8) 
MELD score – mean (SD) 21 (8) 
Child Pugh score – mean (SD) 10 (2) 
INR – median (IQR) 1.8 (0.7) 
Bilirubin (mg/dL) – median (IQR) 3.7 (1.7 – 8.0) 
Albumin (g/dl) – median (IQR) 2.6 (2.2 – 3.0) 
Serum creatinine (µmol/L) – median (IQR) 1.1 (0.8 – 1.9) 
Serum sodium (mmol/L) – mean (SD) 133 (7) 
Leukocytes (x 109/L) – median (IQR) 8.4 (5.2 – 13.0) 
C-reactive protein (mg/L) – median (IQR)° 35 (15 – 77) 
Legend: n, number; SD, standard deviation; HCV, hepatitis C virus; HBV, hepatitis B virus; NASH, non 
alcoholic fatty liver disease, ACLF, acute-on-chronic liver failure; MELD, model of end stage liver 
disease; INR, international normalized ratio; *, 129 patients had more than one etiology of cirrhosis; °, 
available in 1,102 patients 
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The mean age was 57 ± 13 years old and 69% of patients were male. Alcohol consumption was 
the most common etiology of cirrhosis followed by HCV infection and NASH. The patients had 
advanced liver disease as shown by the high prevalence of ascites, hepatic encephalopathy and 
the mean MELD score and CTP score. Notably, 35% of patients had ACLF at the diagnosis of 
infection. Among potential risk factor for MDR bacterial infections, 130 patients (10%) were on 
quinolones prophylaxis, 376 (29%) on treatment with rifaximin, 574 (44%) received an antibiotic 
treatment for at least 5 days in the previous 3 months and 569 (44%) underwent to invasive 
procedures the month before the admission. Finally, 69 patients had the isolation of MDR 
bacteria in the previous 6 months. 
Table 1.2. Characteristics of the first infection. 
Variable N= 1,302 
Site of infection – n (%) 
   Urinary tract infection 
   Spontaneous bacterial peritonitis 
   Pneumonia 
   Spontaneous bacteremia 
   Skin and soft tissue infections 
   Other 
 
289 (22) 
354 (27) 
242 (19) 
100 (8) 
101 (8) 
216 (17) 
Type of infection – n (%) 
   Community acquired 
   Health care acquired 
   Nosocomial 
 
628 (48) 
336 (26) 
338 (26) 
SIRS – n (%)* 405 (36) 
qSOFA – n (%)* 255 (23) 
Septic shock – n (%) 143 (14) 
Positive culture – n (%) 740 (57) 
Number of strains isolated 925 
Type of strain isolated – n (%) 
   Gram – 
   Gram + 
   Fungi 
 
536 (58) 
351 (38) 
38 (4) 
Most frequently isolated bacteria – n (%) 
   Escherichia Coli 
   Klebsiella Pneumoniae 
   Staphylococcus aureus 
   Enterococcus faecalis 
   Enterococcus Faecium 
 
222 (30) 
104 (14) 
58 (8) 
40 (5) 
39 (5) 
MDR bacteria – n (%)° 322 (35) 
XDR bacteria – n (%)§ 73 (8) 
Legend: SIRS, systemic inflammatory response syndrome; qSOFA, quick sequential organ failure assessment; MDR, 
multi drug resistant; XDR, Extensively drug resistant; *, available in 1,119 patients; °, in 253 patients (34%); §, in 62 
patients (8%) 
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The characteristics of bacterial infections have been reported in table 1.2. The most common 
infections were SBP (27%), UTI (22%) and pneumonia (19%). About one half of the infections 
were community acquired (48%), while there was a similar proportion of HCA and nosocomial 
infections (26%). SIRS and a positivity of qSOFA were found in 36 and 23% of patients, 
respectively, while 14% had septic shock at the diagnosis of infection. Microbiological cultures 
were positive in 57% of patients and globally 925 bacteria were isolated. Gram negative bacteria 
were the most common isolates (57%), while gram negative accounted for 38% of positive 
cultures and only 4% showed positivity for fungi. In details, most commonly isolated bacteria 
were Escherichia Coli and Klebsiella Pneumoniae (among gram negative bacteria) and 
Staphylococcus Aureus and Enterococci among gram positive bacteria. Overall, 322 MDR 
bacteria were isolated in 253 patients (19% of patients; 34% of those with positive cultures). 
Most commonly isolated MDR bacteria were ESBL producing Enterobacteriaceae, methicillin 
resistant Staphylococus Aureus, vancomycin resistant Enterococci, Pseudomonas Aeruginosa 
and Acinetobacter baumannii. Overall, 73 XDR bacteria were isolated in 62 patients (5% of 
patients, 8% of positive cultures). The most common isolated XDR bacteria were carbapenemase 
producing Enterobacteriaceae, Pseudomonas Aeruginosa and Acinetobacter Baumannii. 
 
Prevalence of MDR and XDR bacteria across the different countries 
Relevant differences were observed in the prevalence of MDR and XDR bacterial infections 
across the different centers. Remarkably, MDR bacterial infections were very common in Indian 
centers (73% of isolates), while their prevalence was quite low in North American centers (16% 
in U.S. and 24% in Canada). The prevalence of MDR was quite high also in other Asian centers 
and in Southern American center (Figure 1.1), while there was a relevant variability across 
Europe, ranging from 57% of cultures in Israel and 17% in Russia. 
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Figure 1.1 Prevalence of MDR bacteria across the world 
 
Legend. Light blue identifyes countries with a low prevalence, dark blue those with a high 
prevalence. No data are available for countries reported in grey 
 
Similarly, the prevalence of XDR infections was strikingly high in Indian centers (33% of 
isolates), while ranging between 0 and 16% of isolates in the other countries. In table 1.3 a 
detailed description of the prevalence of MDR bacterial infections and the type of MDR strain 
has been reported. Relevant differences were observed among countries, in particular regarding 
the prevalence of ESBL producing and carbapenemases producing Enterobacteriaceae (CPE) 
and Acinetobacter baumannii. The latter was particularly prevalent in Asian centers. As regards 
CPE it should be highlighted the high prevalence in centers in the North of Europe (France and 
Denmark), a finding unexpected according to the data coming from the European Center for 
Disease Prevention and Control. 
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Table 1.3. Prevalence of infections due to MDR bacteria across countries 
 MDR XDR ESBL producing Enterobacteriaceae MRSA VRE 
Pseudomonas 
Aeruginosa 
Acinetobacter 
baumannii CPE 
India 73 33 21 2 4 5 13 22 
Indonesia 25 0 8 0 0 8 8 0 
South Korea 33 5 8 4 2 3 2 1 
Belgium 33 0 13 0 0 0 0 0 
Denmark 50 17 17 8 0 0 0 17 
France 30 10 0 0 0 0 0 10 
Germany 26 5 11 0 0 0 0 5 
Israel 57 0 43 0 0 0 0 0 
Italy 30 7 8 3 3 3 1 4 
Russia 17 0 17 0 0 0 0 3 
Spain 23 3 6 3 0 6 1 0 
Switzerland 26 0 9 0 0 0 0 0 
Canada 24 0 18 0 0 0 0 0 
U.S.A. 16 3 11 0 3 2 0 0 
Argentina 27 3 17 0 3 4 0 0 
Brazil 31 16 13 0 3 3 3 6 
Chile 39 4 26 0 4 0 0 0 
P value <0.001 <0.001 0.020 0.748 0.982 0.945 <0.001 <0.001 
Legend: Results are reported as percentages of patients with positive cultures. MDR, multi drug resistant; XDR, extensively drug resistant; ESBL, 
extended spectrum beta-lactamases, MRSA, methicillin resistant Staphylococcus Aureus; VRE, vancomycin resistant enterococci; CPE, 
carbapenemases producing Enterobacteriaceae.  
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Variables associated with MDR and XDR infections 
In order to better understand the differences across countries, we performed a univariate and 
multivariate analysis of predictors of infections due to MDR bacteria. 
Table 1.4. Comparison of patients’ characteristics according to the presence or not o an 
infection due to a MDR bacteria 
Variable No MDR (N=487) 
MDR 
(N=253) P 
Geographic area – n (%) 
   India 
   Other Asian centers 
   North Europe 
   South Europe 
   North America 
   South America 
 
23 (5) 
71 (15) 
62 (13) 
191 (39) 
45 (10) 
95 (20) 
 
63 (25) 
34 (13) 
27 (11) 
77 (30) 
9 (4) 
42 (17) 
<0.001 
Age (years) – mean (SD) 58 (13) 56 (13) 0.003 
Gender (Male) – n (%) 305 (63) 177 (70) 0.057 
Mean arterial pressure (mmHg) – mean (SD) 81 (13) 82 (14) 0.560 
Norfloxacin prophylaxis – n (%) 45 (9) 21 (8) 0.772 
Treatment with rifaximin – n (%) 147 (30) 81 (32) 0.669 
Antibiotic treatment in the previous 3 months – n (%) 186 (38) 156 (62) <0.001 
Invasive procedures in the previous month – n (%) 188 (39) 143 (57) <0.001 
Isolation of MDR bacteria in the previous 6 months – n (%) 29 (6) 22 (9) 0.214 
Acute-on-chronic liver failure – n (%) 161 (33) 87 (34) 0.779 
MELD score – mean (SD) 20 (8) 22 (8) 0.023 
Child Pugh score – mean (SD) 9.7 (2.2) 10.2 (2.3) 0.016 
Site of infection – n (%) 
   Urinary tract infection 
   Spontaneous bacterial peritonitis 
   Pneumonia 
   Spontaneous bacteremia 
   Skin and soft tissue infection 
   Other 
 
157 (32) 
94 (19) 
47 (10) 
72 (15) 
25 (5) 
92 (19) 
 
90 (36) 
28 (11) 
58 (23) 
22 (9) 
19 (8) 
36 (14) 
<0.001 
Type of infection – n (%) 
   Community acquires 
   Health care associated 
   Nosocomial 
 
242 (50) 
123 (25) 
122 (25) 
 
75 (30) 
77 (30) 
101 (40) 
<0.001 
SIRS – n (%) 158 (40) 75 (34) 0.138 
qSOFA – n (%) 89 (23) 53 (24) 0.802 
Septic shock – n (%) 64 (13) 41 (16) 0.307 
Leukocytes (x 109/L) – median (IQR) 7.7 (4.4 – 12.1) 8.8 (5.6 – 13.4) 0.003 
C-reactive protein (mg/L) – median (IQR) 32 (12 – 80) 37 (17 – 74) 0.396 
Legend: SIRS, systemic inflammatory response syndrome; qSOFA, quick sequential organ failure 
assessment; MDR, multi drug resistant; MELD, model of end stage liver disease. 
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In the univariate analysis MDR infections were more common in young patients, in male and in 
those with a worse liver function according to MELD and CTP score (Table 1.4). Among known 
risk factors for MDR, the use of antibiotics in the previous 3 months, invasive procedures in the 
previous month, health-care associated infections and nosocomial ones were more frequent in 
those with MDR bacteria than in those without. Surprisingly, norfloxacin prophylaxis was not 
found to be more frequent in patients with MDR infections. Subgroup analysis did not find any 
area of the world in which norfloxacin prophylaxis was found to be associated with a higher risk 
of MDR infections (Figure 1.2) 
 
Figure 1.2. Prevalence of MDR bacteria in patients with or without quinolones prophylaxis 
across the different geographic areas 
 
Legend: MDR, multi drug resistant; Q, quinolones 
 
MDR infections were more commonly observed in patients with UTI, pneumonia and SSTIs than 
those with SBP or spontaneous bacteremia. After adjusting for all these confounders, patients 
from Indian (OR=7.94; p<0.001), Southern American (OR=2.23; p=0.053) and Other Asian 
centers (OR=2.79; p= 0.017) still had an increased risk of infections due to MDR bacteria (Table 
1.5). 
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Table 1.5. Multivariate analysis of predictors of an infection due to a MDR bacteria. 
Variable OR 95% CI P 
Geographic area – n (%)* 
   South America 
   India 
   Other Asian centers 
   North Europe 
   South Europe 
 
2.23 
7.94 
2.79 
1.91 
1.64 
 
0.99 – 5.00 
3.30 – 19.11 
1.20 – 6.46 
0.82 – 4.48 
0.77 – 3.49 
 
0.053 
<0.001 
0.017 
0.136 
0.197 
Antibiotic treatment in the 
previous 3 months 1.92 1.32 – 2.80 0.001 
Site of infection ° 
  UTI 
  Pneumonia 
  Skin and soft tissue infection 
  Other infections 
 
2.48  
3.20 
2.92 
1.45 
 
1.59 – 3.87 
1.83 – 5.59 
1.41 – 6.09 
0.85 – 2.49 
 
<0.001 
<0.001 
0.004 
0.175 
Type of infection§ 
   HCA 
   Nosocomial 
 
1.62 
2.65 
 
1.04 – 2.52 
1.75 – 4.01 
 
0.032 
<0.001 
Legend: OR, odds ratio; CI, confidence interval; UTI, urinary trait infection; HCA, health care 
acquired. *, Northern American patients were used as a reference group; °, spontaneous 
infections (SBP and spontaneous bacteremia) were used as reference group; §, community 
acquired infections were used as reference group. 
 
 
The analysis of variables associated with XDR infections confirmed that patients from Indian 
centers had an increased risk of infections due to XDR bacteria (OR= 20.05; p=0.005 – Table 
1.6). Interestingly, pneumonia showed to be independently associated with a higher risk of 
infections due to XDR bacteria (OR= 2.46; P=0.035). 
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Table 1.6. Multivariate analysis of predictors of an infection due to a XDR bacteria. 
Variable OR 95% CI P 
Geographic area – n (%)* 
   South America 
   India 
   Other Asian centers 
   North Europe 
   South Europe 
 
2.84 
20.05 
2.95 
2.06 
2.54 
 
0.33 – 24.13 
2.46 – 163.10 
0.32 – 27.04 
0.22 – 19.60 
0.32 – 20.11 
 
0.339 
0.005 
0.338 
0.529 
0.376 
Isolation of MDR bacteria in the previous 
6 month 4.88 1.98 – 12.02 0.001 
Site of infection ° 
  UTI 
  Pneumonia 
  Skin and soft tissue infection 
  Other infections 
 
2.04 
2.46 
0.46 
0.80 
 
0.93 – 4.49 
1.07 – 5.65 
0.06 – 3.81 
0.27 – 2.31 
 
0.077 
0.035 
0.474 
0.673 
Type of infection§ 
   HCA 
   Nosocomial 
 
2.52 
5.63 
 
1.05 – 6.09 
2.47 – 12.87 
 
0.039 
0.003 
Legend: OR, odds ratio; CI, confidence interval; MDR, multi drug resistant; UTI, urinary trait 
infection; HCA, health care acquired. *, Northern American patients were used as a reference 
group; °, spontaneous infections (SBP and spontaneous bacteremia) were used as reference 
group; §, community acquired infections were used as reference group. 
 
Clinical impact of MDR infections 
MDR bacterial infections were more difficult to be treaded, being associated with a lower 
efficacy of first line empirical antibiotic treatment, a more frequent need to add a second line 
antibiotic treatment, a longer duration of antibiotic treatment and a lower rate of resolution of the 
infection than those with sensitive bacterial infections (Table 1.7). In addition, patients with 
MDR bacterial infections had a higher incidence of septic shock, need to be transferred to the 
ICU and to need mechanical ventilation or renal replacement therapy RRT) than those with 
sensitive bacterial infections. Length of hospital stay was significantly longer in patients with 
MDR bacterial infections than in those without. Most important, patients with MDR infections 
ha a significantly higher in-hospital and 28-day mortality rate. 
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Table 1.7. Clinical impact of infections due to MDR bacteria. 
Variable 
No MDR 
(N= 487) 
MDR 
(N= 253) P 
Efficacy of first line antibiotic treatment – n (%) 331 (68) 100 (40) <0.001 
Administration of a second line treatment – n (%) 197 (41) 159 (63) <0.001 
Duration of antibiotic treatment (days)– M (IQR) 10 (7 – 15) 12 (7 – 18) 0.013 
Resolution of the infection – n (%) 398 (82) 182 (72) 0.003 
Development of new infections – n (%) 101 (21) 53 (21) 1.000 
Transfer to ICU – n (%)# 94 (23) 72 (36) 0.001 
Development of ACLF during hospitalization – n (%)* 92 (28) 59 (36) 0.118 
Development of septic shock during hospitalization – n 
(%)** 62 (13) 57 (27) <0.001 
Administration of mechanical ventilation – n (%)*** 53 (12) 48 (20) 0.003 
Administration of hemodialysis – n (%) 34 (7) 42 (17) <0.001 
Length of hospital stay (days) – M (IQR) 15 (9 – 26) 18 (10 – 30) 0.032 
In-hospital mortality – n (%)° 97 (21) 75 (31) 0.004 
28-day mortality – n (%)§ 99 (22) 72 (34) 0.002 
Legend: n, %; MDR, multi drug resistant; ICU, intensive care unit; ACLF, acute-on-chronic liver failure; 
#, patients with indication to ICU admission at inclusion (n=121) were excluded from this analysis; *, 
Patients with ACLF at inclusion (n=248) have been excluded from this analysis; **, patients with septic 
shock at inclusion (n= 105) were excluded from this analysis; ***, patients on mechanical ventilation at 
inclusion were excluded from this analysis (n=47) °, patients transplanted during hospitalization (n=25) 
have been excluded from this analysis; § patients transplanted or lost to follow up (n=73) have been 
excluded from this analysis. 
 
 
Microbiological sensitivity of currently suggested guidelines in patients with cirrhosis and 
bacterial infections 
After having shown significant differences in the prevalence of MDR and XDR bacterial 
infections across the different countries we explored the microbiological sensitivity to the current 
suggested empirical antibiotic treatment in patients with cirrhosis and bacterial infections. The 
suggested antibiotic protocol was adequate to guarantee an antibiotic coverage in more than 80% 
of isolated strain in Northern and Southern American centers, in Northern European centers 
while being poorly effective in Indian centers (51%) and just below the 80% threshold in 
Southern Europe (77%) and Asian centers (79%) (Table 1.8). 
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Table 1.8. Microbiological efficacy of currently suggested empirical antibiotic treatment* in patients with cirrhosis and bacterial infections 
across different countries. 
 
Overall 
(N= 740) P value 
South Europe 
(N= 268) 
North 
Europe 
(N= 89) 
South 
America 
(N=137) 
North 
America 
(N=55) 
Indian 
hospitals 
(N= 86) 
Other Asian 
Hospital 
(N= 105) 
P value 
Overall efficacy – n (%) 573 (77) - - 205 (77) 76 (85) 119 (87) 46 (84) 44 (51) 83 (79) <0.001 
Type of infection – n (%) 
  Community acquired 
  HCA* 
  Nosocomial 
 
246 (78) 
170 (85) 
157 (70) 
0.002 
 
83 (77) 
56 (84) 
66 (71) 
 
30 (81) 
21 (81) 
25 (96) 
 
44 (82) 
39 (91) 
36 (90) 
 
21 (78) 
16 (100) 
9 (75) 
 
12 (48) 
12 (65) 
20 (40) 
 
56 (85) 
14 (82) 
13 (59) 
- - 
Site of infection – n (%) 
   UTI 
   SBP 
   Pneumonia 
   Spontaneous Bacteremia 
   SSTI 
   Other 
 
205 (83) 
105 (86) 
67 (64) 
75 (80) 
28 (64) 
93 (73) 
<0.001 
 
77 (84) 
22 (92) 
15 (60) 
34 (79) 
8 (53) 
49 (61) 
 
28 (82) 
24 (92) 
6 (67) 
3 (100) 
3 (60) 
12 (100) 
 
41 (85) 
39 (100) 
8 (73) 
16 (80) 
3 (75) 
12 (80) 
 
16 (73) 
3 (100) 
2 (100) 
9 (100) 
4 (100) 
12 (80) 
 
14 (67) 
6 (50) 
16 (49) 
2 (25) 
4 (50) 
2 (50) 
 
29 (97) 
11 (61) 
20 (80) 
11 (100) 
6 (75) 
6 (46) 
 
- - 
Legend:  HCA, health care associated; UTI, urinary tract infections; SBP, spontaneous bacterial peritonitis; SSTI, skin and soft tissues infections.  
*, treatment suggested by Jalan R et al ref 8 including carbapenems for health care associated and nosocomial infections and excluding glycopeptides 
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The microbiological efficacy of the suggested empirical antibiotic treatment decreased moving 
from community acquired to nosocomial infections, in particular in Asian centers (Table 1.8). 
Considering the treatment suggested for specific type of infection, it is remarkable that treatment 
suggested for pneumonia and SSTI was microbiologically effective only in 64% of isolates 
involved in those infections, while the treatment suggested for UTI, SBP and spontaneous 
bacteremia were quite effective (Table 1.8 and Table 1.9). Interestingly, treatment suggested for 
community acquired pneumonia was microbiologically effective in 83% of isolates and the 
efficacy of empirical antibiotic treatment decrease moving to HCA and nosocomial infections 
(63 and 44%, respectively). Conversely, treatment suggested for community acquired and HCA 
SSTIs had a trend toward less microbiological efficacy than those provided for nosocomial 
episodes. Interestingly, the addition of clindamycin to beta-lactams in community acquire 
infections could improve the microbiological coverage (67 vs 52%), although the difference was 
not significant due to the low number of patients with positive cultures. 
 
Table 1.9. Microbiological efficacy of currently suggested empirical antibiotic treatment* 
in community acquired, health care associated and nosocomial infections in patients with 
cirrhosis. 
 
Community 
acquired  
(N=317) 
Health care 
associated 
(N=200) 
Nosocomial 
(N=223) P value 
Urinary tract infections – n (%) 103 (81) 59 (92) 43 (77) 0.058 
Spontaneous bacterial peritonitis – n (%) 43 (83) 41 (91) 21 (84) 0.464 
Pneumonia – n (%) 31 (84) 20 (63) 16 (44) 0.002 
Spontaneous bacteremia – n (%) 30 (79) 11 (79) 34 (81) 0.968 
Skin and soft tissues infections – n (%) 13 (52) 5 (63) 10 (91) 0.082 
Other – n (%) 26 (68) 34 (92) 33 (62) 0.006 
Legend: *, treatment suggested by Jalan R et al ref 8 including carbapenems for health care 
associated and nosocomial infections and excluding glycopeptides. 
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Then, we tried to simulate different approach for health care associated infections considering: a) 
the feasibility of a strategy including treatment provided for community acquired infections (that 
may reduce the exposure to broad spectrum antibiotics); b) a broad spectrum antibiotic treatment 
with the administration of piperacillin/tazobactam (Pip/Tazo) instead than carbapenems (that 
may reduce the exposure to carbapenems and the risl of XDR infections) c) a broad spectrum 
treatment including glycopeptides (Table 1.10). 
 
Table 1.10.  Microbiological efficacy of different empirical antibiotic strategies for health 
care associated infections in patients with cirrhosis and bacterial infections across different 
countries 
 
Treatment 
including 
carbapenems° 
Treatment with 
Pip/Tazo+ 
Treatment suggested 
for community 
acquired infections 
Treatment including 
carbapenems and 
glicopeptides § 
Overall efficacy – n (%) 170 (85) 140 (70)*** 126 (63)*** 175 (88) 
Site of infection – n (%) 
  UTI 
  SBP 
  Pneumonia 
  Spontaneous Bacteremia 
  SSTI 
  Other 
 
59 (92) 
41 (91) 
20 (63) 
11 (79) 
5 (63) 
34 (92) 
 
52 (81) 
34 (76) 
11 (34)* 
11 (79) 
- - 
27 (73) 
 
46 (72)* 
31 (69)* 
10 (31)* 
9 (64) 
4 (50) 
26 (70)* 
 
59 (92) 
41 (91) 
22 (69) 
12 (86) 
7 (88) 
34 (92) 
South Europe 56 (84) 46 (69) 40 (60)* 60 (90) 
North Europe 25 (96) 23 (89) 19 (73)* 26 (100) 
South America 39 (91) 35 (81) 31 (72)* 39 (91) 
North America 16 (100) 13 (81) 13 (81) 16 (100) 
Indian hospitals 20 (65) 11 (36)* 12 (39) 20 (65) 
Other Asian Hospital 14 (82) 12 (71) 11 (65) 14 (82) 
Legend: UTI, urinary tract infections; SBP, spontaneous bacterial peritonitis; SSTI, skin and soft tissues 
infections.  
°, treatment suggested by Jalan R et al ref 8 including carbapenems for health care associated and 
nosocomial infections and excluding glycopeptides. 
+, treatment suggested by Jalan R et al ref 8 excluding the use of carbapenems and glycopeptides for 
health care associated and nosocomial infections. 
§, treatment suggested by Jalan R et al ref 8 including the use of carbapenems and glycopeptides for 
health care associated and nosocomial infections. 
*** p<0.001 vs treatment including carbapenems 
* p<0.05 vs treatment including carbapenems 
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The treatment provided for community acquired infections had a lower efficacy than the standard 
one for all the infections and for all the centers excepting for North American centers, in which it 
had an acceptable microbiological efficacy (81%). The use of Pip/Tazo instead of carbapenems 
had a significantly lower overall microbiological efficacy than the treatment including 
carbapenems (70 vs 85%; p<0.001) being less effective in the treatment of SBP, pneumonia and 
other infections, although the level of significance was reached only for pneumonia. 
Interestingly, the microbiological efficacy of Pip/Tazo reached 81% of UTI and 79% of 
spontaneous bacteremia. In addition, it was quite effective in Northern European centers and in 
Southern and Northern American centers (microbiological efficacy >80%) being a good 
alternative to carbapenems in these centers. The addition of glycopeptides did not improve the 
efficacy of an antibiotic regimen based on carbapenems.  
Moving to nosocomial infections the treatment with Pip/Tazo showed a significantly lower 
microbiological efficacy than treatment including carbapenems considering all the infections (55 
vs 70%; p<0.001), UTI (55 vs 77%; p<0.05) and SBP (48 vs 84%; p<0.05). Pip/Tazo based 
regimens were less effective than carbapenem based regimens in all the countries although 
reached the level of significance only in Southern American centers.  
An empirical antibiotic treatment containing both carbapenems and glycopeptides had a 
significantly higher microbiological efficacy than a carbapenem based antibiotic regimen (80 vs 
70%; p<0.05) although the level of significance was reached only for less common infections. 
The combination of glycopeptides and carbapenems improved the antimicrobial coverage of 12% 
in pneumonia, although it did not reach the level of significance and the microbial coverage was 
still very low. When Indian patients were excluded from the analysis (due to the high prevalence 
of A. baumannii and CPE) the combination of carbapenems and glycopeptides (plus quinolones) 
significantly improved the microbiological efficacy when compared to carbapenems alone (plus 
quinolones) (71 vs 40%; p= 0.011). Regarding the different geographic areas, the combination of 
carbapenems and glycopeptides was significantly more effective than the use of only 
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carbapenems in South European centers (85 vs 71%; p<0.05) and had a trend toward the 
significance for Asian centers other than India (86 vs 59%). Conversely, the combination of 
carbapenems and glycopeptides had similar antimicrobial coverage than carbapenems alone in 
American and Northern European centers. 
 
Table 1.11.  Microbiological efficacy of different empirical antibiotic strategies for health 
care associated infections in patients with cirrhosis and bacterial infections across different 
countries 
 
Treatment 
including 
carbapenems° 
Treatment with 
Pip/Tazo+ 
Treatment including 
carbapenems and 
glicopeptides § 
Overall efficacy – n (%) 157 (70) 122 (55)*** 179 (80)* 
Site of infection – n (%) 
  UTI 
  SBP 
  Pneumonia 
  Spontaneous Bacteremia 
  SSTI 
  Other 
 
43 (77) 
21 (84) 
16 (44) 
34 (81) 
10 (91) 
33 (62) 
 
31 (55)* 
12 (48)* 
10 (28) 
30 (71) 
10 (91) 
29 (55) 
 
45 (80) 
22 (88) 
20 (56) 
34 (81) 
11 (100) 
47 (89)* 
South Europe 66 (71) 57 (61) 79 (85)* 
North Europe 21 (81) 17 (65) 23 (89) 
South America 36 (90) 25 (63)* 36 (90) 
North America 9 (75) 7 (58) 9 (75) 
Indian hospitals 12 (40) 5 (17) 13 (43) 
Other Asian Hospital 13 (59) 11 (50) 19 (86) 
Legend:  UTI, urinary tract infections; SBP, spontaneous bacterial peritonitis; SSTI, skin and soft tissues 
infections.  
°, treatment suggested by Jalan R et al ref 8 including carbapenems for health care associated and 
nosocomial infections and excluding glycopeptides. 
+, treatment suggested by Jalan R et al ref 8 excluding the use of carbapenems and glycopeptides for 
health care associated and nosocomial infections. 
§, treatment suggested by Jalan R et al ref 8 including the use of carbapenems and glycopeptides for 
health care associated and nosocomial infections. 
*** p<0.001 vs treatment including carbapenems 
* p<0.05 vs treatment including carbapenems 
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Discussion 
The most relevant finding of this study is the wide variability in the prevalence and the type of 
MDR bacteria in patients with cirrhosis and bacterial infections. The very high prevalence of 
MDR (3/4 of isolates) and XDR (1/3 of isolates) in Indian center is worrying. This findings were 
already shown in patients without cirrhosis and are probably related to the antibiotic misuse 
observed in India[93]. Another explanation may be related to the prevalence of the New Delhi 
metallo-β-lactamase 1 (NDM-1) which confers resistance to carbapenems and can be easily 
transferable to other Enterobacteriaceae[94]. In addition, a high prevalence of Acinetobacter 
baumannii was found both in India and in other Asian center, which lead to a poor efficacy of 
currently available antibiotics. Remarkably, even in community acquired infections the 
prevalence of MDR infections was very high in Indian center.  
As previously shown[11], MDR infections were more difficult to be treated being less responsive 
to the empirical antibiotic treatment and being associated with a lower resolution rate. 
Furthermore, they were associated with a higher incidence of septic shock, transfer to the ICU 
and short-term mortality. Considering that the initiation of an effective empirical antibiotic 
treatment is the strongest predictor of survival in patients with cirrhosis and bacterial 
infections[13,76] and the relevant regional differences in the epidemiology of these infections, 
we explored the probability of antimicrobial efficacy of the currently recommended antibiotic 
regimen in these patients[8]. The results of this analysis have potential relevant implications for 
clinical practice. The first expected finding is that Indian centers have a very poor antimicrobial 
coverage with currently suggested recommendations and need to develop local strategies. 
Considering the lack of effective antibiotics they would probably need to use old antibiotics 
usually avoided in patients with cirrhosis, such as aminoglycosides and to develop strategies of 
prevention of development of further resistance. In fact, it will be very important to avoid an 
irrational use of new effective antibiotics against Pseudomonas Aeruginosa and CPE such as 
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ceftolozane/tazobactam and ceftazidime/avibactam, respectively[95,96]. Interestingly the 
antimicrobial efficacy of suggested regimens was very good in all the types of SBP, spontaneous 
bacteremia and UTI. Conversely, the antibiotic regimens suggested for HCA and nosocomial 
pneumonia are poorly effective, as well as those provided for community acquired SSTIs. The 
addition of glycopeptides in the former and of clindamycin in the latter may improve the chances 
of antimicrobial efficacy. 
Coming back to the regional differences it should be highlighted that the antimicrobial coverage 
for community acquired, HCA and nosocomial infections was very good in Northern European 
and American centers. Interestingly, in Northern American center, HCA infections could be 
safely treated with the regimen provided for community acquired infections. In addition, HCA 
infections may be treated avoiding carbapenems, thus with the use of Pip/Tazo based regimens in 
Northern European and Southern American centers, avoiding the early use of carbapenems for 
those infections. Conversely, the use of carbapenems could provide better coverage in HCA 
infections in Southern European centers and Asian centers, confirming the finding of a 
randomized controlled trial performed in Italy[70]. 
Moving to nosocomial infections, it should be highlighted that the use of Pip/Tazo instead of 
carbapenems provided a lower antimicrobial coverage in all the centers and it should be taken 
into account, particularly in critically ill patients. Conversely, the combination of carbapenems 
and glycopeptides provided a significantly better coverage, particularly in Southern European 
centers. As suggested above, the use of glycopeptides in addition to carbapenems could provide a 
better coverage in pneumonia and in other more rare infections (cholangitis, secondary 
bacteremia etc.)[97].  
Although the early initiation of an effective antibiotic treatment is a main goal of the 
management of patients with cirrhosis, the prevention of further antibiotic resistance is of 
equivalent importance. While waiting for the wide distribution of rapid tests for antimicrobial 
resistance, such as MALDI-TOF, an early de-escalation of antibiotic treatment should be 
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performed as soon as possible. In our cohort, when we compared patients who de-escalated 
antibiotic treatment versus those who did not change the treatment (those who received an 
escalation were excluded), no difference was found in terms of resolution of infections (92 vs 
89%; p= N.S.), development of ACLF (18 vs 24%; p= N.S.), septic shock (8 vs 9%; p= N.S.) or 
in-hospital mortality (12 vs 13%). These findings suggest that de-escalation of antibiotic 
treatment is feasible and should be implemented. Another important result of our study is that no 
difference was found in the prevalence of MDR bacteria between patients treated or not with 
norfloxacin prophylaxis. This results was unexpected and in contrast with previous findings[11]. 
The reason is not clear and should be further explored, however quinolones prophylaxis should 
be still prescribed when indicated both in primary[98,99] and in secondary prophylaxis[100].  
The study has several strengths, being the largest study performed in patients with cirrhosis and 
bacterial infections, with a prospective design in several centers across the world. However, it 
also has potential limitations: the detailed mechanisms of resistance were not studied, although 
several countries were included, many countries remained excluded from the study due to lack of 
man power or lack of interest in participating to the study. Another potential limitation is related 
to the fact that participating centers were tertiary referral hospitals and the epidemiology may be 
different in other scenarios in the same country. Finally, the microbiological efficacy of 
antibiotics does not necessarily mean clinical efficacy. However, considering that large 
multicenter intercontinental interventional studies about the use of antibiotics in patients with 
cirrhosis are unlikely to be performed in future, the findings of this study may help in clinical 
decisions-  
In conclusion, this study helped to understand better the epidemiology of infections across the 
world and allowed some suggestions about empirical antibiotic treatment n patients with 
cirrhosis and bacterial infections 
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STUDY 2:  
ASSESSMENT OF SEPSIS-3 CRITERIA AND QUICK SOFA IN 
PATIENTS WITH CIRRHOSIS AND BACTERIAL INFECTIONS 
 
Introduction 
As reported in the background and methods section, early diagnosis, treatment, and prognostic 
stratification of patients with cirrhosis and sepsis are crucial[101]. It is well known that the SIRS 
criteria for the diagnosis of sepsis have poor accuracy in patients with cirrhosis and bacterial 
infections. In fact, patients with cirrhosis may have: a) leukopenia due to hypersplenism, b) 
tachypnea due to hepatic encephalopathy or ascites, c) bradycardia due to the use of beta-
blockers[8,13]. Recently, a panel of experts proposed new diagnostic criteria for the definition of 
sepsis in the general population[84]. These criteria define sepsis as a life-threatening organ 
dysfunction caused by a dysregulated host response to infection. Thus, the fulcrum of the 
definition has been targeted from systemic inflammation to organ dysfunction which is now 
defined as an acute change in sequential organ failure assessment (SOFA) score≥2 points 
(Sepsis-3). In addition, a new simplified score, the quick SOFA (qSOFA) score, has been 
proposed for the screening of sepsis outside of the intensive care unit (ICU). The qSOFA is 
considered positive when at least 2 among the following criteria are present (alteration of 
consciousness; respiratory rate≥22/min; systolic blood pressure≤100 mmHg). This new measure 
provides simple bedside criteria to identify adult patients with suspected infection who are likely 
to have poor outcomes. Although qSOFA is less robust than Sepsis-3 in the ICU, it does not 
require laboratory tests and can be assessed quickly and repeatedly. Thus, the qSOFA should be 
used to prompt clinicians to further investigate for organ dysfunction and to consider an increase 
in the frequency of monitoring. Both these criteria have been validated in large series of patients 
inside and outside the ICU[102–104]. Nevertheless, both of these new scores have never been 
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tested for prognostic assessment in patients with cirrhosis and bacterial infection so far. 
Unlike the qSOFA, the timely application of Sepsis-3 in clinical practice depends on the 
availability of a SOFA score before the development of the bacterial infection (baseline SOFA 
score), particularly in patients with a medical history of chronic diseases[84]. However, it should 
be recognized that a baseline SOFA score was not available in most of the patients who were 
enrolled in the above mentioned studies. This shortcoming in the application of the Sepsis-3 
criteria has been overcome assuming that the baseline SOFA was equal to zero in patients who 
were admitted to the hospital with a bacterial infection. This assumption could be misleading in 
patients with cirrhosis, who may have a baseline SOFA higher than zero due to: low platelet 
count, high values of bilirubin and/or some degree of hepatic encephalopathy.  
Thus, the aim of this study was to assess both the applicability and the prognostic accuracy of 
Sepsis-3 criteria and qSOFA in patients with cirrhosis and bacterial infections.  
 
Materials and methods 
Patients  
The study was performed in patients from 2 different cohorts. The primary cohort included 
consecutive patients with cirrhosis and bacterial or fungal infections admitted to the University 
Hospital of Padua, in Italy, from January 2011 to August 2016. The validation cohort included 
consecutive patients with cirrhosis and bacterial or fungal infections admitted to the University 
Hospital of Bologna, in Italy, from March 2014 to February 2016. The patients were 
prospectively enrolled in the 2 cohorts with the aim to assess the epidemiology and clinical 
impact of bacterial/fungal infections at each center. The primary end points of the study were: 
prevalence and risk factors for multi-drug resistant bacterial infections and risk factors for in-
hospital, 28-day mortality and 90-day mortality. The studies were subsequently amended 
including Sepsis-3 and qSOFA assessment. Inclusion criteria were: a) diagnosis of cirrhosis 
according to histological, clinical, biochemical, ultrasonographic and/or endoscopic findings; b) 
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diagnosis of bacterial and/or fungal infection during hospitalization; c) age>18 years old. 
Exclusion criteria were: a) hepatocellular carcinoma (HCC) beyond the Milan criteria; b) 
extrahepatic malignancy; c) severe extrahepatic disease (congestive heart failure stage NYHA≥2, 
chronic obstructive pulmonary disease stage GOLD≥2; chronic kidney disease requiring renal 
replacement therapy[RRT]); d) previous transplant; e) HIV infection; f) use of 
immunosuppressive drugs.  
The protocol was approved by the local Ethics Committee at each center and all patients 
provided written informed consent. 
 
Design of the study 
Once informed consent was obtained, a physical examination, routine laboratory and 
microbiological analyses were performed. Demographic, clinical, laboratory and microbiological 
data, as well as treatment administered were collected. SOFA score was calculated according to 
these variables[105]. In patients without data on PaO2, respiratory score was calculated using 
oxygen saturation/fraction inspired oxygen ratio, has previously suggested and validated both in 
general population and in patients with cirrhosis (Table 2.1)[5,106]. Since the Sepsis-3 criteria 
were published in February 2016, the preadmission values of SOFA score were retrospectively 
collected from outpatient/day hospital visits and/or previous hospitalizations (variables at 
discharge) as suggested for the application of International Club of Ascites acute kidney injury 
(ICA-AKI) criteria[74]. In patients without a preadmission SOFA score the baseline was: a) the 
first SOFA assessment at hospital admission (for those with nosocomial infections); b) 
considered equal to zero as previously suggested[84]. Scores of liver disease such as Model of 
End-Stage Liver Disease (MELD), Child-Turcotte Pugh (CTP), chronic liver failure-SOFA 
(CLIF-SOFA) and CLIF consortium acute decompensation (CLIF-C-AD) scores, were calculated 
at the diagnosis of infection. 
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Table 2.1: Sequential Organ Failure Assessment (SOFA) score° 
System  
Score 
0 1 2 3 4 
Coagulation 
   Platelet (×103/µL)  
 
≥150 
 
<150 
 
<100 
 
<50 
 
<20 
Liver 
   Bilirubin (mg/dL) 
 
<1.2 
 
1.2–1.9 
 
2.0–5.9 
 
6.0–11.9 
 
>12.0 
Kidney 
   Creatinine (mg/dL)  
 
<1.2 
 
1.2–1.9 
 
2.0–3.4 
 
3.5–4.9 
 
>5.0 
Central nervous system 
   GCS  
 
15 
 
13–14 
 
10–12 
 
6–9 
 
<6 
Cardiovascular # MAP ≥70 mm Hg MAP <70 mm Hg 
Dopamine <5 or 
dobutamine or 
terlipressin 
Dopamine 5.1–15 or 
adrenaline ≤0.1 or 
noradrenaline ≤0.1 
Dopamine >15 or 
adrenaline >0.1 or 
noradrenaline >0.1 
Respiration 
   PaO2/FIO2  (mmHg) 
   SatO2/FIO2   
 
≥400 
>512 
 
<400 
<512 
 
<300 
<357 
 
<200* 
<214* 
 
<100* 
<89* 
Legend: GCS, glasgow coma scale; MAP, mean arterial pressure; PaO2 partial pressure of oxygen; FIO2, fraction of inspired oxygen; SatO2, 
oxygen saturation; #, Catecholamine doses are given as μg/kg/min; * with respiratory support. °Adapted from references 93-94 
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Bacterial/fungal infections were classified as community acquired (CA), health-care associated 
(HCA) and nosocomial infections as previously shown[11]. Bacterial/fungal infections were 
diagnosed according to standard criteria already reported in the Study 1[60,89]: 
Patients were followed-up until death, liver transplantation(LT) and/or discharge. Patients 
discharged before 90 days were followed up until 90 days from the diagnosis of infection. Data 
on the development of new bacterial/fungal infections, septic shock, AKI, ACLF, the transfer to 
the ICU, the use of vasopressors, mechanical ventilation and/or RRT during the hospitalization 
were collected. If the patients had second infections and/or new admissions for infections during 
the study period, only the first episode was considered for the purpose of the study. 
 
Definitions 
Sepsis, according to Sepsis-3 criteria, was defined by an acute increase of SOFA score≥2 
points[84]. Delta SOFA was assessed at admission in patients with CA or HCA infections, while 
the time frame for the assessment of delta SOFA was 24 hours for patients with nosocomial 
infections. The qSOFA was considered positive when at least 2 among the following criteria 
were present (alteration of consciousness; respiratory rate≥22/min; systolic blood pressure≤100 
mmHg)[84]. SIRS was defined by the presence of at least 2 among the following criteria (body 
temperature<36°C or >38°C; heart rate>90 bpm, respiratory rate>20/min, white blood cells 
[WBC]<4.000/µL or>12.000/µL or immature neutrophils>10%). Septic shock was defined as 
hypotension requiring use of vasopressors to maintain mean arterial pressure (MAP)≥65 mmHg 
and having a serum lactate level greater than 2 mmol/L despite adequate fluid resuscitation[84]. 
Bacteria were defined as MDR when resistant to at least one antibiotic in 3 or more classes[91]. 
ACLF was defined and graded according to the EASL-CLIF consortium definition[5]. 
AKI was defined and staged according to International Club of Ascites criteria[74].  
The efficacy of first line treatment was defined according to the clinical and laboratory 
improvement. The resolution of infections was defined by the clinical improvement, the 
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disappearance of signs and symptoms of infection, negative microbiological cultures and the 
improvement of laboratory and/or radiological examinations. 
 
Management of sepsis 
Patients were empirically treated with antibiotics according to the available international 
recommendation[107,108] and local epidemiology (high prevalence of resistance to quinolones, 
ESBL-producing Enterobacteriaceae and Enterococci). From 2014, patients were treated 
according to EASL recommendations[8]. A group of patients with nosocomial SBP were 
involved in a randomized controlled trial and treated with meropenem plus daptomycin[67]. In 
case of positive cultures, antibiotic treatment was adjusted according to an antibiotic 
susceptibility test. Patients with septic shock received resuscitation with plasma expanders and 
vasopressors. Patients with type-1 hepatorenal syndrome were treated with vasoconstrictors plus 
albumin. 
 
Statistical analysis 
The primary end point of the study was in-hospital mortality. Secondary end-points were 28-day 
mortality, development of ACLF, AKI, septic shock, transfer to the ICU, and need for organ 
support (mechanical ventilation or RRT) during the hospitalization. For estimating sample size, 
we hypothesized that the primary end-point would have occurred in 20% and 5% in patients with 
or without Sepsis-3, respectively. We expected two third of patients with cirrhosis and bacterial 
infections to meet Sepsis-3 criteria and a drop-out rate of 10 % due to LT, thus 257 patients were 
needed to detect this difference with a 2-sided type-1 error rate of 5% and a power of 90%. 
Continuous variables were summarized as mean ± standard deviation or median with interquartile 
range (IQR) according to normal or non-normal distribution, respectively. They were compared 
using Student's T-test or Mann-Whitney U test, respectively. Categorical variables were reported 
as proportions and compared with chi-square or Fisher’s exact test. Cumulative incidence of in-
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hospital and 28-day mortality was calculated considering LT as a competing event. Cumulative 
incidence curves were compared using Gray's test.  Univariate and multivariate Cox regression 
analyses of predictors of mortality were performed using a competing risk approach with the Fine 
and Gray method and results expressed as p-value, subdistribution hazard ratios (sHR) and their 
95% confidence intervals (95% CI). Variables found to be associated with in-hospital mortality 
with a p-value<0.1 in the univariate analysis were included in a multivariate analysis, with 
stepwise backward elimination (entry p<0.05; drop p>0.1). Variables that by definition could not 
be available within 24 hours from the diagnosis of infection (i.e. results of cultures, development 
of new infections and/or new organ failures, response to antibiotic treatment, transfer to the ICU 
etc.) were not included in the multivariate analysis. Non-normally distributed continuous 
variables were log-transformed to be included in the multivariate models. When Sepsis-3, SIRS, 
and qSOFA and/or scores of liver disease were included in the model their components were 
excluded to avoid multicollinearity. Similarly, in case of a correlation>0.5 between scores of 
liver disease and above mentioned criteria, the scores were not included in the model to avoid 
multicollinearity. The discrimination ability of Sepsis-3, SIRS, and qSOFA was assessed with 
the area under the receiver operating characteristic (AUROC) using the continuous scores. The 
AUROCs were compared according to the DeLong method. All tests were two-tailed and P-
values<0.05 were considered significant. The statistical analysis was performed using SPSS 
statistical package, version 23.0, MedCalc Software, version 16.2 and SAS version 9.4. 
 
Results 
Primary cohort 
During the study period, 317 patients hospitalized for an acute decompensation of cirrhosis and 
with bacterial/fungal infections were evaluated. Among them, 58 were excluded for several 
reasons and 259 patients were enrolled. In Figure 2.1 a flow chart of patients evaluated in the 
study has been reported.  
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Figure 2.1. Flow chart of the study. 
 
Legend: N, number; HCC, hepatocellular carcinoma 
 
The baseline characteristics of patients included are reported in Table 1. The mean age was 
61±12 years. The most common etiologies of cirrhosis were alcohol consumption and HCV 
infection. The majority of patients had an advanced liver disease as shown by the high prevalence 
of ascites, hepatic encephalopathy and the prognostic scores. Sixty-eight patients (26%) had 
ACLF and ninety-four (36%) AKI at the diagnosis of infection. Increased levels of C-reactive 
protein (CRP) were found in most patients (median=22 mg/L; upper normal value=6 mg/L). A 
baseline SOFA score was available in 207 patients (80%) with a median of 4 (IQR 2-5). The 
median time elapsed from baseline assessment and the onset of bacterial infection was 21 days 
(IQR 7-51). All patients were enrolled while in a regular ward. Patients were followed-up for a 
median of 86 days (IQR 29 - 90). 
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Table 2.2. Demographic, clinical and laboratory characteristics of patients at the diagnosis 
of infection in primary cohort. 
Variables N = 259 
Age (years) – mean (SD) 61 (12) 
Gender (Male) – n (%) 162 (62) 
Etiology of cirrhosis – n (%) 
   HBV                                                                                  
   HCV 
   Alcohol 
   HCV + Alcohol 
   Other 
 
23 (9) 
78 (30) 
104 (40) 
22 (9) 
32 (12) 
Diabetes – n (%) 83 (32) 
MAP (mmHg) – mean (SD) 83 (12) 
HR (bpm) – mean (SD) 83 (17) 
Body temperature (°C) – mean (SD)  37 (1) 
Respiratory rate (breath/min) – mean (SD) 19 (4) 
Ascites – n (%) 216 (83) 
Hepatic encephalopathy – n (%) 94 (36) 
ACLF – n (%) 68 (26) 
ACLF grade – n (%) 
  Grade 1 
  Grade 2 
  Grade 3 
 
45 (66) 
20 (30) 
3 (4) 
MELD score – mean (SD) 20 (7) 
Child Pugh score – mean (SD) 9 (2) 
CLIF-C AD score – mean (SD) 58 (11) 
INR – median (IQR) 1.5 (1.3 – 1.9) 
Bilirubin (µmol/L) – median (IQR) 64 (32 – 142) 
Albumin (g/dl) – median (IQR) 29 (25 - 34) 
SCr (µmol/L) – median (IQR) 100 (73 - 155) 
Sodium (mmol/L) – mean (SD) 133 (6) 
Platelets (x 109/L) – median (IQR) 91 (56 - 146) 
Leukocytes (x 109/L) – median (IQR) 6.6 (4.4 – 10.5) 
CRP (mg/L) - median (IQR) 22 (12 - 54) 
SOFA score baseline* - median (IQR) 4 (2 – 5) 
SOFA score inclusion – median (IQR) 6 (4 – 7) 
CLIF-SOFA score inclusion – median (IQR) 6 (4 – 8) 
Legend: M, median; m, mean; IQR, interquartile range; SD, standard deviation; n, number; 
HBV, hepatitis B virus; HCV, hepatitis C virus; MAP, mean arterial pressure; HR, heart rate; 
MELD, model for end-stage liver disease; CLIF-C AD, chronic liver failure consortium acute 
decompensation score; ACLF, acute-on-chronic liver failure; INR, international normalized ratio; 
SCr, serum creatinine; C-reactive protein; SOFA, sequential organ failure assessment; CLIF, 
chronic liver failure; *, available in 207 patients. 
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Characteristics of bacterial infections 
UTI was the most common infection in our series (33%), followed by SBP (23%), pneumonia 
(13%) and primary bacteremia(13%) (Table 2.3).  
 
Table 2.3. Clinical and microbiological characteristics of bacterial infections in primary 
cohort 
Variable N= 259 
Site of infection – n (%) 
   UTI 
   SBP 
   Pneumonia 
   Primary bacteremia 
   Skin and soft tissue infection 
   Others# 
 
85 (33) 
59 (23) 
36 (14) 
35 (13) 
15 (6) 
29 (11) 
Type of infection – n (%) 
   CA 
   HCA 
   Nosocomial 
 
82 (32) 
89 (34) 
88 (34) 
SIRS – n (%)* 89 (34) 
Positive qSOFA score– n (%) 60 (23) 
Sepsis according to Sepsis-3 criteria – n (%) 166 (64) 
Septic shock – n (%) 6 (2) 
Positive microbiological cultures – n (%) 191 (74) 
Type of strains isolated – n (%) 
   Gram – 
   Gram + 
   Fungi 
 
87 (46) 
90 (47) 
14 (7) 
Type of bacteria isolated – n (%) 
   Escherichia Coli 
   Enterococcus Faecium 
   Klebsiella Pneumoniae 
   Enterococcus faecalis 
   Staphylococcus aureus 
   Other Enterobacteriaceae 
   Other Staphylococci 
   Others 
 
43 (22) 
30 (16) 
21 (11) 
20 (10) 
5 (3) 
12 (6) 
24 (13) 
36 (17) 
MDR Bacteria– n (%) 79 (30) 
Legend: n, number; UTI, urinary trait infection; SBP, spontaneous bacterial peritonitis; CA, community 
acquired; HCA, health-care associated; SIRS, systemic inflammatory response syndrome; qSOFA, quick 
SOFA score; MDR, multi drug resistant.  
#, 6 secondary bacterial peritonitis, 4 chlostridum difficile colitis, 4 spontaneous bacterial empyema, 12 
infections without identified focus, 2 secondary bacteremia, 1 cholangitis,  
*,70 patients (27%) had no SIRS criteria, 100 (39 %) had 1 SIRS criteria, 63 (24) had 2 SIRS criteria, 22 
(9) had 3 SIRS criteria and 4 (2%) 4 SIRS criteria. 95 patients (37%) had WBC criteria, 29 (11%) body 
temperature criteria, 113 (44%) respiratory rate criteria and 71 (27%) heart rate criteria. 
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There was a balanced proportion between CA (32%), HCA (34%), and nosocomial infections 
(34%). At least one microbiological culture was positive in 191 patients (74%), with a balance 
between Gram-positive and Gram-negative strains (47 and 46%, respectively), while fungi were 
isolated in 7% of patients (mainly Candida species). The most common bacterium was 
Escherichia coli (22%), followed by Enterococcus faecium (16%) and Klebsiella pneumoniae 
(11%). Seventy-nine patients (30%) showed an infection due to multi-drug resistant (MDR) 
bacteria. At the diagnosis of infection, 89 patients (34%) had SIRS, 60 (23%) had a positive 
qSOFA, and 166 (64%) fulfilled Sepsis-3 criteria. Sepsis-3 was significantly more common in 
patients without an available baseline SOFA than in those with a baseline SOFA score (94 vs 
57%; p<0.001). In addition, Sepsis-3 was significantly more common in patients with a positive 
qSOFA than in those with a negative qSOFA (87 vs 57%; p<0.001). Conversely, no difference 
was found in the prevalence of Sepsis-3 among those with or without SIRS (P=0.10). Regarding 
empirical antibiotic treatment, 149 patients (58%) were treated with 2 or more antibiotics. The 
most used antibiotics were third generation cephalosporins (34%), quinolones (34%), 
carbapenems (34%), glycopeptides (22%) and piperacillin/tazobactam (18%). The empirical 
antibiotic treatment was effective in 206 patients (79%) and the final resolution of infection was 
achieved in 217 patients (84%). Fifty-three patients developed a second infection during the 
hospitalization.  
 
Survival 
During the hospitalization 45 patients died (17%), 19 were transplanted (7%) and 195 survived 
(75%). In Table 2.4, a comparison of baseline characteristics of survivors versus non-survivors 
has been reported. Non-survivors had a significantly worse alteration of vital signs, liver and 
renal function than survivors. Markers of systemic inflammation such as leukocytes and CRP 
were found to be significantly higher in non-survivors than survivors.  
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Table 2.4. Demographic, clinical and laboratory characteristics of survivors vs non-
survivors* in primary cohort 
Variables Survivors (N=195) 
Nonsurvivors 
(N=45) sHR (95% CI) 
P 
value 
Age (years) – media (DS) 62 (12) 61 (10) 1.02 (0.99-1.04) 0.235 
Gender (M) – n (%) 117 (60) 33 (73) 1.65 (0.86-3.14) 0.130 
Etiology of cirrhosis – n (%) (Alcohol) 80 (41) 20 (44) 1.18 (0.66-2.10) 0.581 
Treatment with β-blockers – n (%) 64 (34) 16 (37) 1.01 (0.55-1.83) 0.985 
Diabetes – n (%) 66 (34) 12 (27) 0.84 (0.44-1.59) 0.590 
Ascites – n (%) 158 (81) 41 (91) 1.95 (0.77-4.93) 0.159 
Hepatic encephalopathy – n (%) 62 (32) 25 (56) 2.48 (1.38-4.44) 0.002 
Respiratory rate (breath/min)– mean (SD) 18 (4) 21 (4) 1.13 (1.05-1.21) 0.001 
Body temperature (°C) – media (DS) 36.6 (1) 37 (1) 1.35 (1.07-1.70) 0.012 
MAP (mmHg) – mean (SD) 85 (11) 81 (13) 0.99 (0.96-1.02) 0.363 
Heart rate (bpm) – mean (SD) 81 (14) 87 (18) 1.01 (1.00-1.03) 0.064 
INR – median (IQR) 1.5 (1.3 – 1.8) 1.8 (1.6 – 2.1) 3.19 (1.92-5.28) < 0.001 
Bilirubin (µmol/L) – median (IQR) 53 (27 – 105) 119 (63 – 293) 1.06 (1.03-1.09) < 0.001 
Albumin (g/L)– mean (SD) 31 (6) 27 (6) 0.94 (0.89-0.99) 0.012 
SCr (µmol/L) – median (IQR) 93 (69 – 142) 132 (79 – 197) 1.33 (1.17-1.52) 0.021 
Serum Sodium (mmol/L) – media (DS) 134 (6) 131 (6) 0.93 (0.90-0.97) 0.002 
CRP (mg/L) – median (IQR) 21 (10 – 52) 35 (15 – 79) 1.01 (1.00-1.01) 0.019 
Leukocytes (x 109/L) – median (IQR) 5.9 (4.2–9.2) 9.8 (4.7–13.3) 1.03 (1.00-1.07) 0.081 
Platelets (x 109/L) – median (IQR)  95 (59 – 141) 78 (46 – 150) 1.00 (0.99-1.00) 0.551 
MELD score – mean (SD) 18 (7) 26 (7) 1.11 (1.06-1.16) < 0.001 
Child Pugh score – mean (SD) 9 (2) 11 (1) 1.85 (1.47-2.32) < 0.001 
Delta SOFA – median (IQR) 2 (1 – 4) 4 (3 – 7) 1.26 (1.14-1.39) < 0.001 
CLIF – SOFA score – median (IQR) 6 (4 – 7) 8 (7 – 10) 1.50 (1.30-1.72) < 0.001 
CLIF-AD score – mean (SD) 56 (10) 65 (10) 1.07 (1.04-1.10) < 0.001 
AKI at inclusion – n (%) 62 (32) 24 (53) 5.46 (2.40-12.50) <0.001 
ACLF at inclusion – n (%) 41 (21) 18 (40) 1.61 (0.87-2.97) 0.128 
SIRS – n (%) 62 (32) 23 (51) 2.24 (1.25-3.98) 0.007 
Positive qSOFA score – n (%) 31 (16) 23 (51) 3.18 (1.76-5.71) < 0.001 
Sepsis-3 criteria – n (%) 114 (58) 42 (93) 7.75 (2.38-25.00) 0.001 
Nosocomial infections – n (%) 54 (28) 21 (47) 1.09 (0.60-1.99) 0.780 
MDR bacteria – n (%) 53 (27) 20 (44) 1.27 (0.71-2.26) 0.791 
Efficacy of empirical antibiotic treatment – 
n (%) 180 (92) 8 (18) 22.92 (10.83-48.52) < 0.001 
Resolution of infection – n (%) 194 (99) 5 (11) 52.4 (21.2-129.6) < 0.001 
Development of septic shock during 
hospitalization – n (%) 9 (5) 16 (36) 4.50 (2.54-7.94) < 0.001 
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Variables Survivors (N=195) 
Nonsurvivors 
(N=45) sHR (95% CI) 
P 
value 
Trasfer in ICU – n (%) 9 (5) 20 (44) 7.94 (4.50-14.09) < 0.001 
Mechanical ventilation – n (%) 3 (1) 6 (13) 4.07 (2.00-8.20) 0.002 
RRT – n (%) 4 (2) 5 (11) 2.37 (1.02-5.53) 0.046 
Legend: sHR, subdistribution hazard ratio; CI, confidence interval; M, median; m, mean; IQR, 
interquartile range; SD, standard deviation; n, number; MAP, mean arterial pressure; MELD, model for 
end-stage liver disease; CLIF-C AD, chronic liver failure consortium acute decompensation score; AKI, 
acute kidney injury; ACLF, acute-on-chronic liver failure; INR, international normalized ratio; SCr, 
serum creatinine; C-reactive protein; SOFA, sequential organ failure assessment; CLIF, chronic liver 
failure; SIRS, systemic inflammatory response syndrome; qSOFA, quick SOFA score; MDR, multi drug 
resistant; ICU, intensive care unit; RRT, renal replacement therapy; *, liver transplantation was 
considered a competing event of death. 
 
The prevalence of SIRS, Sepsis-3, and positive qSOFA was significantly higher in non-survivors 
than survivors (51 vs 32 %, sHR=2.24; p=0.007; 93 vs 58%, sHR=7.75, p=0.001; and 51 vs 
16%, sHR=3.18,  p<0.001, respectively). As expected, a high MELD score, hepatic 
encephalopathy and AKI were all associated with a worse survival rate. An ineffective antibiotic 
treatment was also found to be strongly associated with a worse survival rate. Interestingly, no 
difference was found in in-hospital mortality rate according to beta-blockers use. In the 
multivariate analysis, after excluding MELD and CLIF-SOFA for collinearity with Sepsis-3 
criteria, Sepsis-3 (sHR=5.47; p=0.006), positive qSOFA (sHR=1.99; p=0.020), CLIF-C-AD 
score (sHR=1.05; p=0.001) and CRP (sHR=1.01; p=0.034) were found to be independent 
predictors of in-hospital mortality (Table 4). The multivariate analysis of 28-day mortality 
showed similar results. More in detail, Sepsis-3 criteria(sHR=3.57; p=0.016), positive qSOFA 
(sHR=2.23; p=0.013) and CLIF-C-AD score (sHR=1.05; p=0.001)were found to be independent 
predictors of 28-day mortality.  
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Table 2.5. Multivariate analysis of in-hospital and 28-day mortality in patients with 
cirrhosis and bacterial/fungal infections in primary cohort 
Variable sHR 95% CI P 
In-hospital mortality 
Sepsis-3 criteria 5.47 1.65 – 18.18 0.006 
qSOFA criteria 1.99 1.12 – 3.55 0.020 
CRP (g/L) 1.01 1.00 – 1.01 0.034 
CLIF-C-AD 1.05 1.01 – 1.08 0.001 
28-day mortality 
Sepsis-3 criteria 3.57 1.27 – 9.99 0.016 
qSOFA criteria 2.23 1.19 – 4.20 0.013 
CLIF-C-AD 1.05 1.02 – 1.08 0.001 
Legend: sHR, subdistribution hazard ratio; CI, confidence interval; Sepsis-3, diagnosis of sepsis 
according to Sepsis-3 criteria; qSOFA, quick sequential organ failure assessment score; CRP, C-
reactive protein; CLIF-C-AD; chronic liver failure consortium acute decompensation score. 
 
 
The cumulative incidence of 28-day mortality was significantly higher in patients with Sepsis-3 
than in those without (23 vs 4%; p=0.001) (Fig.1 panel-A). In-hospital mortality rate was not 
significantly different between patients with Sepsis-3 with or without a baseline SOFA score 
(29vs21%; p= 0.396). 
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Figure 2.2. Cumulative incidence of 28-day mortality according to fulfillment or not of 
Sepsis-3 criteria in primary cohort 
 
Legend: Comparison was done using Gray’s test 
 
 
Likewise, patients with a positive qSOFA score had a significantly higher cumulative incidence 
of 28-day mortality than those with a negative qSOFA score (32 vs 13%; p<0.001) (Figure 2.3).  
 
Figure 2.3. Cumulative incidence of 28-day mortality according to the positivity of quick 
SOFA (qSOFA) score in primary cohort 
 
Legend: pos, positive; neg, negative. Comparison was done using Gray’s test 
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In patients without a baseline SOFA score the combination of both Sepsis-3 and a positive 
qSOFA helped to identify a group of patients with a worse 28-day mortality that was similar to 
the one observed in patients with a baseline SOFA and Sepsis-3 (30% and 26%, respectively). 
Conversely, 28-day mortality was not significantly different between patients without a baseline 
SOFA and only Sepsis-3 (negative qSOFA) and those without Sepsis-3 (11 vs 6%; p=0.164) 
(Figure 2.4). 
 
Figure 2.4. Cumulative incidence of 28-day mortality comparing patients without sepsis 
with those without a baseline SOFA score and only Sepsis-3 criteria or both Sepsis-3 
criteria and a positive quick SOFA (qSOFA) in primary cohort 
 
Legend: pos, positive; *, p= 0.006 vs No Sepsis; #, p= 0.164 vs No sepsis. Comparison was done 
using Gray’s test. 
 
 In the subgroup of patients without ACLF or septic shock patients with Sepsis-3 and positive 
qSOFA had a significantly higher incidence of 28-day mortality than those without (18 vs 6%, 
p=0.015 and 24 vs 11%, p=0.018, respectively; Figure 2.5 panel A and panel B, respectively).  
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Figure 2.5. Cumulative incidence of 28-day mortality according to fulfillment or not of 
Sepsis-3 criteria (panel A) or the positivity of quick SOFA (qSOFA, panel B) in patients 
without ACLF/septic shock 
 
 
 
Legend: pos, positive; neg, negative. Comparison was done using Gray’s test. 
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Interestingly, even in patients with ACLF 28-day incidence of mortality was significantly higher 
in patients with Sepsis-3 or positive qSOFA than those without (34 vs 0%, p<0.001 and 44 vs 
20%, p=0.013). Overall, the AUROC of Sepsis-3 criteria and qSOFA in predicting in-hospital 
mortality was 0.784 (95% CI=0.729-0.833) and 0.732 (95% CI=0.674-0.785), respectively and it 
was significantly higher than the one of SIRS (0.606; 95% CI=0.544-0.666; p<0.001 and 
p=0.006, respectively) (Fig. 2.6).  
 
Figure 2.6: Receiver Operating Characteristic curves for in-hospital mortality of Sepsis-3 
criteria, systemic inflammatory response syndrome (SIRS) criteria and quick sequential 
organ failure assessment (qSOFA) in the primary cohort. 
 
Legend: Sepsis-3 indicates the delta increase in SOFA score; SIRS and qSOFA the final scores 
given by each SIRS and qSOFA point, respectively. *, p<0.01 vs SIRS. 
 
In addition, the discrimination ability of 28-day mortality of Sepsis-3 (AUROC=0.737; 95% 
CI=0.676-0.792) and qSOFA (AUROC=0.718; 95% CI=0.656-0.774) was significantly better 
than SIRS (AUROC=0.609; 95% CI=0.544-0.672; p=0.019 and 0.015, respectively). The use of 
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a CLIF-SOFA derived “criterion” (delta CLIF-SOFA) to define sepsis did not significantly 
improve the prognostic accuracy of Sepsis-3 criteria. 
 
Outcomes of infections according to Sepsis-3 and qSOFA 
During the hospitalization, 48 patients (25%) developed ACLF, 25 (10%) septic shock and 46 
(19%) AKI (Table 2.6). Thus, overall, 116 patients (45%) had ACLF, 31 patients had septic 
shock (12%), and 140 patients had AKI (54%). 
 
Table 2.6. Outcomes of bacterial infections during follow up. 
Variable N = 259 
Response to empirical antibiotic treatment– n (%) 206 (79) 
Resolution of infection – n (%) 217 (84) 
Development of AKI – n (%)* 46 (28) 
Development of septic shock – n (%)** 25 (10) 
Development of ACLF – n (%)*** 48 (25) 
Transfer in ICU – n (%) 29 (11) 
Mechanical ventilation – n (%) 9 (3) 
RRT – n (%) 10 (4) 
In-hospital mortality – n (%)  45 (19) 
28-day mortality – n (%) 40 (15) 
90-day mortality – n (%) 61 (24) 
Legend: AKI, acute kidney injury; ACLF, acute on chronic liver failure; ICU, intensive care unit; 
renal replacemt therapy.  
*, patients with AKI at inclusion (n=94) were excluded from this analysis;  
** patients with septic shock at inclusion (n=6) were excluded from this analysis 
***patients with ACLF at inclusion (n=68) were excluded from this analysis 
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Twenty-nine patients (11%) were transferred to the ICU, 9 required mechanical ventilation (3%) 
and 10 RRT (4%). As expected, patients developing AKI, ACLF and/or septic shock had a 
significantly higher mortality rate than those who did not (45 vs 3%, 60 vs 1%, 64 vs 13%, 
respectively; all p<0.001) as well as patients admitted to the ICU (69 vs 12%, p<0.001), or those 
mechanically ventilated (67 vs 17%, p=0.002) or on RRT (56 vs 17%, p=0.013).  
Patients with Sepsis-3 and a positive qSOFA had a significantly lower rate of response to 
empirical antibiotic treatment (72 vs 93%, p<0.001; 62 vs 85%; p<0.001, respectively) and of 
final resolution of the infection (77 vs 97%, p<0.001; 67 vs 89%; p<0.001, respectively) than 
those without (Tables 2.7 and 2.8). Furthermore, patients with Sepsis-3 and positive qSOFA had 
a significantly higher probability of developing ACLF (36 vs 11%; p<0.001; 44 vs 21%; 
p=0.001, respectively) and to be transferred to the ICU (16 vs 2%; p=0.001; 23 vs 7%; p=0.002, 
respectively) and to need mechanical ventilation (5 vs 0%; p=0.029; 10 vs 2%; p=0.006, 
respectively) than those without (Tables 2.7 and 2.8). Only patients with Sepsis-3 had a higher 
incidence of septic shock (15 vs 0%; p<0.001) and a need for RRT (6 vs 0%; p=0.016) than those 
without. 
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Table 2.7. Outcomes of bacterial infections during follow up in patients with vs without 
Sepsis-3 criteria. 
Variables 
No sepsis 
(N=93) 
Sepsis-3 
(N=166) P value 
Efficacy of empirical antibiotic treatment – n 
(%) 
86 (92) 120 (72) < 0.001 
Resolution of infection – n (%) 90 (97) 127 (77) < 0.001 
Development of AKI – n (%)* 15 (21) 31 (33) 0.132 
Development of ACLF – n (%)** 9 (11) 39 (36) < 0.001 
Development of septic shock during 
hospitalization – n (%)*** 
0 (0) 25 (15) < 0.001 
Trasfer in ICU – n (%) 2 (2) 27 (16) 0.001 
Mechanical ventilation – n (%) 0 (0) 9 (5) 0.029 
RRT – n (%) 0 (0) 10 (6) 0.016 
In-hospital mortality – n (%)# 3 (3) 42 (25) 0.001 
28-day mortality – n (%)# 4 (4) 36 (22) 0.001 
90-day mortality – n (%)# 9 (10) 52 (31) <0.001 
Legend: n, number; AKI, acute kidney injury; ACLF, acute-on-chronic liver failure; ICU, 
intensive care unit; RRT, renal replacement therapy;  
*, patients with AKI at inclusion (n=94) were excluded from this analysis;  
**, patients with ACLF at inclusion (n=68) were excluded from this analysis 
***, patients with septic shock at inclusion (n=6) were excluded from this analysis 
#, comparison made with competing risk analysis (Fine and Gray test) 
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Table 2.8. Outcomes of bacterial infections during follow up in patients with positive 
qSOFA vs those with negative qSOFA. 
Variables 
qSOFA neg 
(N=199) 
qSOFA pos 
(N=60) P value 
Efficacy of empirical antibiotic treatment – n 
(%) 169 (85) 37 (62) < 0.001 
Resolution of infection – n (%) 177 (89) 40 (67) < 0.001 
Development of AKI – n (%)* 34 (25) 12 (39) 0.204 
Development of ACLF – n (%)** 33 (21) 15 (44) 0.009 
Development of septic shock during 
hospitalization – n (%)*** 18 (9) 7 (12) 0.724 
Trasfer in ICU – n (%) 15 (7) 14 (23) 0.002 
Mechanical ventilation – n (%) 3 (2) 6 (10) 0.006 
RRT – n (%) 5 (3) 5 (8) 0.095 
In-hospital mortality – n (%)# 22 (11) 23 (38) <0.001 
28-day mortality – n (%)# 21 (11) 19 (32) <0.001 
90-day mortality – n (%)# 36 (18) 25 (42) <0.001 
Legend: n, number; AKI, acute kidney injury; ACLF, acute-on-chronic liver failure; ICU, 
intensive care unit; RRT, renal replacement therapy;  
*, patients with AKI at inclusion (n=94) were excluded from this analysis;  
**, patients with ACLF at inclusion (n=68) were excluded from this analysis 
***, patients with septic shock at inclusion (n=6) were excluded from this analysis 
#, comparison made with competing risk analysis (Fine and Gray test) 
 
Validation cohort 
The external validation cohort included 197 patients with cirrhosis and bacterial and/or fungal 
infections followed for a median of 90 days (IQR=86-90). A comparison between validation 
cohort and primary cohort has been reported in Supplementary Table 8. Demographic 
characteristics were similar between the 2 groups. Patients in the validation cohort were less 
frequently alcoholics and had a less advanced liver disease as shown by the lower rate of ascites 
and the lower values of MELD score, CTP score and SOFA score. The rate of patients fulfilling 
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Sepsis-3 was significantly lower in the validation cohort than in the primary cohort (50 vs 64%; 
p=0.004) as well as the rate of patients with a positive qSOFA (12 vs 24%; p=0.004). 
Conversely, no difference was found in the prevalence of SIRS criteria. In-hospital mortality was 
not significantly different between the 2 cohorts, while LT rate was higher in the primary cohort 
than in the validation cohort. Even in the validation cohort Sepsis-3 was significantly more 
common in patients without an available baseline SOFA than in those with a baseline SOFA 
score (95 vs 46%; p<0.001) and in patients with a positive qSOFA than in those with a negative 
qSOFA (92 vs 45%; p<0.001). Similarly to the primary cohort, no difference was found in the 
prevalence of Sepsis-3 among those with or without SIRS (P=0.810). In the validation cohort 
both Sepsis-3 criteria (AUROC=0.797; 95% CI=0.734-0.851) and qSOFA (AUROC=0.784; 95% 
CI=0.720-0.839) confirmed a significantly better discrimination ability for in-hospital mortality 
than SIRS criteria (AUROC=0.631; 95% CI=0.560-0.699 [Sepsis-3 vs SIRS, p=0.009; qSOFA 
vs SIRS; p=0.009]; Fig. 2.8). Moreover, the discrimination ability for 28-day mortality of Sepsis-
3 (AUROC=0.813; 95% CI=0.751-0.865) and qSOFA (AUROC=0.779; 95% CI=0.714-0.835) 
were significantly better than SIRS (AUROC=0.632; 95% CI=0.561-0.700; p=0.006 and 0.017, 
respectively). 
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Figure 2.7. Receiver Operating Characteristic curves for in-hospital mortality of Sepsis-3 
criteria, systemic inflammatory response syndrome (SIRS) criteria and quick sequential 
organ failure assessment (qSOFA) 
 
Legend: Sepsis-3 indicates the delta increase in SOFA score; SIRS and qSOFA the final scores 
given by each SIRS and qSOFA point, respectively. *, p<0.01 vs SIRS. 
 
 
Discussion 
An accurate prognostic assessment in patients with cirrhosis and bacterial infection is crucial for 
their management in clinical practice. Until now, it has been based on the characterization of the 
bacterial infection as sepsis, severe sepsis, and septic shock, on the development of organ 
failure/s, and/or on CTP and MELD scores. Moving from the definition of sepsis, which has been 
based on SIRS criteria, it should be recognized that this approach has some relevant drawbacks. 
It is well known that SIRS criteria have significant shortcomings when applied to patients with 
cirrhosis. Beyond this, it should be emphasized that recently, according to the Third International 
Consensus Definition for sepsis and septic shock, they have now been abandoned also in the 
general population in favor of new evidence-based criteria. Specifically, a new criterion has been 
validated, namely, the Sepsis-3 which is defined as an acute change in SOFA score≥2 points. In 
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addition, a new simplified tool, namely qSOFA, has been validated for the screening in patients 
with suspected bacterial infection in order to provide simple bedside criteria to identify patients 
with suspected infection who are likely to have poor outcomes. 
Neither Sepsis-3 criteria nor qSOFA have been tested and validated in patients with cirrhosis and 
bacterial infection so far. Thus, the main result of the study was to show that the definition of 
sepsis based on the Sepsis-3 criteria has a better prognostic accuracy than the one based on the 
SIRS criteria. The relevance of this finding has been further strengthened by the external 
validation. This finding is probably related to two factors: a) the shortcoming of SIRS criteria, b) 
the deep prognostic impact of organ dysfunction, detected by Sepsis-3 criteria, in patients with 
cirrhosis. The latter is not surprising. In fact, the Canonic study has been clearly shown that organ 
dysfunction is a strong predictor of mortality in patients with an acute decompensation of 
cirrhosis[5]. Although the discrimination ability of both sepsis-3 criteria and qSOFA was far 
from being perfect (a finding already shown in general population)[102–104], they were able to 
identify patients at risk of short term mortality even in a potential low risk group (no ACLF, no 
septic shock). Interestingly, even in high risk group (patients with ACLF), both Sepsis-3 and 
qSOFA criteria identified a group with a very high short-term mortality rate. These data suggest 
that when ACLF and organ failures are acutely precipitated by a bacterial infection the prognosis 
is the worst.  
One potential criticism of our study is that the diagnosis of sepsis according to Sepsis-3 criteria 
was very common in both the primary and the validation cohorts. This is due to the critical role 
of having or not having a baseline SOFA score. After all, it is sufficient that a patient has a 
platelet count<150,000 due to hypersplenism and a total bilirubin≥1.2 mg/dl due to a mild liver 
dysfunction for a delta SOFA score≥2 if the baseline is not available and thus, is assumed to be 
equal to 0. Such confirming, both in the primary cohort and the validation cohort the prevalence 
of Sepsis-3 was significantly lower in patients with a baseline SOFA score than in those without. 
Despite this limitation, no significant difference was found in terms of in-hospital mortality 
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between patients diagnosed with sepsis with or without a baseline SOFA (29 vs 21%; p=0.396). 
It means that organ dysfunctions are so important that are able to identify patients with bacterial 
infections with a poor prognosis regardless of the presence or not of a baseline SOFA. But the 
question arises: to what extent was organ dysfunction related to bacterial infections in patients 
with cirrhosis in whom the baseline SOFA was not available? Therefore, Sepsis-3 criteria should 
be interpreted and applied with caution in these patients. Probably, the only way to exceed this 
shortcoming is the sequential application of the algorithm proposed for patients outside the ICU, 
which provides in the first instance the use of qSOFA in the assessment of patients with bacterial 
infections[84]. In fact, the qSOFA does not include parameters of liver as well as coagulation 
function that are so frequently impaired in patients with cirrhosis even without infections. In 
addition, about 90% of patients with a positive qSOFA meet Sepsis-3 criteria being highly 
suggestive of the presence of sepsis induced organ dysfunction. Such confirming the positivity of 
both qSOFA and Sepsis-3 in patients without a baseline SOFA score was associated with a 
dramatic reduction of the probability of 28-day survival. According to these concepts, a new 
algorithm has been proposed that is specifically devoted to the application of Sepsis-3 criteria 
and qSOFA in the management of hospitalized patients with cirrhosis and bacterial infection 
(Fig. 2.8). According to this algorithm, if a baseline SOFA score is available when the diagnosis 
of bacterial infection is made or suspected, the Sepsis-3 criteria can be applied. On the contrary, 
when a baseline SOFA score is not available both qSOFA and Sepsis-3 criteria should be 
applied. If both the criteria are positive, the patient should be intensively cared for, since they 
predict a high probability of a worse outcome, while the absence of both the criteria identify a 
group of patients with a very good outcome. Moreover, the only positivity of the Sepsis-3 in 
these patients should be interpreted with caution since it doesn’t necessarily reflect the 
consequence of the bacterial infection on organ functions and, probably, a close monitoring of 
the SOFA score should be advised in the management.  
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Figure 2.8. 
 
Legend: SOFA, sequential organ failure assessment; qSOFA, quick sequential organ failure 
assessment; ICU, intensive care unit 
 
Moving from the clinical ground to pathophysiology, it should be highlighted that the degree of 
inflammation still plays a crucial role on the outcome of patients with cirrhosis and bacterial 
infections. This is proven by the finding that CRP was among the independent predictors of in 
hospital survival. Finally, it should be highlighted that the ability of CLIF-C-AD score in 
predicting mortality is well explained by the fact that it intercepts both the degree of 
inflammation, through the WBC count, and the clinical consequences of a bacterial infection, 
through its other variables (creatinine, serum sodium concentration and INR) in patients with 
cirrhosis[109].  
In conclusion, our study shows for the first time that the qSOFA and the Sepsis-3 criteria are 
more accurate than the SIRS criteria to identify patients with cirrhosis and bacterial or fungal 
infections with a worse outcome. In more detail, the presence of Sepsis-3 when a baseline value 
of the SOFA score is available or with a simultaneous positivity of qSOFA, can be considered as 
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a reliable basis to define sepsis in these patients. The only positivity of Sepsis-3 criteria in 
patients without a baseline value of SOFA score and without a simultaneous positivity of 
qSOFA, should be interpreted with caution, because they do not necessarily reflect a bacterial-
related organ dysfunction. 
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STUDY 3: 
PREDICTORS OF EARLY READMISSION IN PATIENTS WITH 
CIRRHOSIS AFTER THE RESOLUTION OF BACTERIAL INFECTIONS 
 
Introduction 
Thirty-day and 3-month hospital readmissions occur in about 20-35% and 35-50% of patients 
with cirrhosis, respectively[85,86,110–116]. These rates are higher than those reported in general 
population in the US (20% and 34%, respectively)[117]. Hospital readmissions represent a very 
limiting factor for the quality of life, and, thus, a key parameter in the evaluation of the quality of 
care in patients with cirrhosis. The identification of the causes of early readmission is critical in 
reducing readmission rates and, thus, improving the quality of care. In a large, multicenter 
prospective study conducted in the US, 3-month readmission was found to be associated with 
MELD score, diabetes, and nosocomial infections[86]. Taking into account all of the other 
studies on the same matter, the final conclusion was quite similar, leading to a general 
recommendation such as “close monitoring of patients at high risk of early readmission is 
mandatory”. The close monitoring outpatients with cirrhosis, in a setting of a new model of 
specialist care, has already been proven to be successful in reducing the burden of hospital 
readmissions[85]. Nevertheless, the question remains: “can we take further preventive measures 
before discharging the patient?” Looking at the results of the previously cited US multicenter 
prospective study[86], nosocomial infections featured prominently among the discharge variables 
when readmissions due to infections, HE or renal/metabolic causes were considered. The 
relevance of infection as a predictor of early readmission led us to plan a prospective study to 
identify predictors of 30-day readmission in a specific cohort of cirrhotic patients, such as that of 
patients who were discharged after the resolution of a bacterial and/or fungal infection. 
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Methods 
Patients  
The study was conducted evaluating all consecutive patients with cirrhosis and ascites discharged 
from the General Hospital of Padova from January 2010 until June 2016 after a hospitalization 
for a bacterial or fungal infection. Inclusion criteria were the following: a) diagnosis of liver 
cirrhosis confirmed by liver biopsy or by combination of clinical, radiological and biochemical 
markers; b) age >18 years; c) diagnosis of bacterial infection and/or fungal infection at first 
hospital admission or during first hospitalization. Exclusion criteria were the following: a) acute 
or subacute liver failure without underlying cirrhosis; b) presence of active malignancy (except 
HCC within the Milan criteria) or previous malignancies with less than five years of negative 
follow-up; c) moderate to severe chronic heart failure (NYHA≥2); d) severe chronic obstructive 
pulmonary disease (GOLD stage≥ 2); e) severe psychiatric disorders; f) ongoing or recent 
immunosuppressant therapy; g) previous organ transplant; h) HIV infection; i) refusal to provide 
written informed consent. The protocol was approved by the local Ethics Committee and all 
patients provided written informed consent. 
 
Study protocol 
After identification of the bacterial infection and the signature of informed consent, the patients 
entered in a screening period during the hospitalization. During this period, data regarding 
demographic, clinical, laboratory, and microbiological data at the time of diagnosis of infection 
were collected, in addition to information regarding antibiotic treatment administered. Events 
that occurred during the hospitalization such as the development of acute kidney injury (AKI), 
acute-on-chronic liver failure (ACLF) or second infections were also collected. Patients were 
treated with antibiotics according to the available international recommendations[8,107] and 
local epidemiology. The decision to discharge the patient was made by the attending physicians 
according to clinical and laboratory data. Those patients who survived through hospitalization 
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entered in the study protocol and clinical and laboratory data, as well as treatment administered, 
were reassessed on the day of discharge. Patients were followed up regularly after being 
discharged for a period of at least 6 months, or until liver transplantation, or death. During the 
follow up, data on new hospital admissions and/or bacterial infections were collected in the study 
charts. In cases where patients did not attend the visits, a telephone contact was performed with 
the patients, family members, or the primary physicians. For the purpose of the study, all 
unprogrammed urgent hospital readmissions were defined as "readmission". Patients hospitalized 
for planned procedures (execution of radiological, endoscopic, hemodynamic procedures or 
programmed paracentesis) were not considered "readmissions". Early readmissions were defined 
as all unprogrammed, urgent hospital readmissions which occurred within 30 days from 
discharge. Data regarding the cause of readmission, infections during the readmission as well as 
microbiological and clinical data at the time of readmission were collected. For each patient, 
more than 200 variables among demographic and clinical data, vital signs, biochemical, 
microbiological and radiological tests, hepatic and/or extrahepatic organ failures and treatment 
administered, were evaluated at the time of diagnosis of infection, during hospitalization, at 
discharge, and during the follow-up period. 
 
Diagnostic criteria and definitions 
Infections were diagnosed according to the Centers for Disease Control and Prevention 
Criteria[89]. These criteria have been reported in detail in Study 1. Infections were classified as 
community acquired infections (CA), health care associated infections (HCA), and nosocomial 
infections as previously shown. Patients who had second infections during the hospitalization 
were considered as having ha a nosocomial infection. Bacteria were defined as multi-drug 
resistant (MDR) when resistant to at least one antibiotic in 3 or more classes[91]. 
ACLF was defined according to the EASL-CLIF consortium criteria[5]. AKI was defined 
according to the International Club of Ascites criteria[74]. 
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Statistical analysis 
The primary end point of the study was the occurrence of an early hospital readmission. Patients 
lost to follow up immediately after discharge were excluded from the analysis. Continuous 
variables were reported as mean and standard deviation for those with normal distribution, and as 
median and IQR for those not normally distributed. Categorical variables were reported as 
frequency and percentage. Comparison between groups was performed using Wilcoxon-Mann-
Whitney and Students’ T test for normally and not normally distributed continuous variables, 
respectively and chi-square test or Fisher's exact test for categorical variables. Variables with 
p<0.1 at univariate analysis between patients readmitted or not within 30 days after discharge, 
were included in multivariate logistic regression analysis with a stepwise backward elimination 
(entry p<0.05; exit p>0.10). Results are reported as OR with a 95% confidence interval. The 
survival curves were developed using the Kaplan Meier method and compared with the Log 
Rank test. Variables with p<0.1 at univariate analysis between survivors and deaths within 6 
months after discharge, were included in a multivariate Cox proportional hazards model with 
stepwise backward elimination (0.05 entry, exit 0.10). Results were presented as the HR with a 
95% confidence interval. All tests were bilateral, and statistical significance was considered for 
p<0.05. Data were processed using the SPSS Statistics version 23.0. 
 
Results 
Study population 
Two-hundred-ten consecutive patients with cirrhosis discharged from the hospital after an 
episode of bacterial or fungal infection were enrolled. Eleven patients were excluded from the 
analysis because they were lost to follow up immediately after discharge, thus 199 patients were 
included in the final analysis. 
Baseline characteristics of patients have been reported in Table 3.1.  
 76 
 
Table 3.1. Characteristics of the study population 
Variables Whole population (N= 199) 
Age (years) – m (SD) 61 (13) 
Gender (male) – n (%) 117 (59) 
Etiology – n (%) 
  Alcohol 
  HCV 
  HBV 
  Other 
 
82 (41) 
72 (36) 
16 (8) 
29 (15) 
Diabetes – n (%) 65 (33) 
Charlson comorbidity score – m (SD) 4.4 (1.9) 
Admitted in the previous 90 days – n (%) 73 (37) 
Nosocomial infections – n (%) 77 (39) 
Main type of infection – n (%) 
  Urinary tract infections 
  Spontaneous bacterial peritonitis 
  Pneumonia 
  Skin and soft tissue infections 
  Spontaneous bacteremia 
  Other 
 
84 (42) 
36 (18) 
28 (14) 
24 (12) 
15 (8) 
12 (6) 
SIRS during admission – n (%) 89 (45) 
AKI during admission – n (%) 71 (36) 
ACLF during admission – n (%) 52 (26) 
Heart rate (bpm) – m (SD)* 81 (16) 
Mean arterial pressure (mmHg) – m (SD)* 84 (12) 
Ascites - n (%)* 182 (92) 
Refractory ascites – n (%) 63 (32) 
Hepatic encephalopathy – n (%)* 31 (16) 
White blood cell count (x 10^9/L) – M (IQR)* 5.2 (3.4 – 7.1) 
C- reactive protein (mg/L) – M (IQR)* 12.6 (6.4 – 22.7) 
Bilirubin (µmol/L) – M (IQR)* 41 (23 – 71) 
INR – M (IQR)* 1.4 (1.2 – 1.6) 
Serum creatinine (µmol/L) – M (IQR)* 79 (61 – 110) 
Albumin (g/dl) – M (IQR)* 2.9 (2.5 – 3.3) 
MELD score – m (SD)* 15 (5) 
Child Pugh score – m (SD) 8 (7 – 10) 
CLIF-c AD score – m (SD) 50 (8) 
Length of hospital stay (days) – M (IQR) 15 (9 – 27) 
Duration of antibiotic treatment (days) – M (IQR) 10 (7-19) 
Antibiotic treatment at discharge – n (%) 67 (34) 
Norfloxacin prophylaxis – n (%)* 40 (20) 
Legend: n, number; m, mean; SD, standard deviation; M, median; IQR, interquartile range; SIRS, systemic 
inflammatory responses syndrome; AKI, acute kidney injury; ACLF, acute-on-chronic liver failure; MELD, model of 
end stage liver disease; CLIF-c AD, Chronic Liver Failure consortium acute decompensation score. *, variables 
collected at discharge 
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The mean age was 61±13 years and the majority were male (59%). Urinary tract infection (UTI) 
was the most common infection followed by SBP and pneumonia (42%, 18% and 14%, 
respectively). Those infections were community acquired in 75 patients (38%), health care 
associated in 47 (24%) and nosocomial in 77 (39%). Microbiological cultures were positive in 
128 patients (64%), and 54 patients (27%) had an infection due to a MDR bacteria, mainly ESBL 
producing Enterobacteriaceae (n=14), Enterococcus faecium (n=14) and MRSA (4) (Table 3.2).  
 
Table 3.2. Microbiological cultures during the hospitalization 
Positive cultures* N= 167 
Blood cultures – n (%) 43 (26) 
Urine cultures – n (%) 83 (49) 
Ascitic fluid cultures – n (%) 16 (10) 
Other – n (%) 25 (15) 
Isolated strains N= 192 
Enterobacteriaceae – n (%) 
   Escherichia Coli  
   Klebsiella pneumoniae  
   Proteus mirabilis  
   Morganella spp.  
   Enterobacter spp. 
80 (44)  
54 (29)  
12 (7)  
4 (2)  
3 (2)  
3 (2) 
Enterococci – n (%) 
   Enterococcus faecalis  
   Enterococcus faecium 
45 (25)  
21 (12)  
23 (13) 
Staphylococci – n (%) 
   Staphylococcus aureus 
24 (13)  
10 (5) 
Streptococci – n (%) 4 (2) 
Pseudomonas Aeruginosa – n (%) 3 (2) 
Acinetobacter baumannii – n (%) 2 (1) 
Stenotrophomonas maltophilia – n (%) 2 (1) 
Candida spp. – n (%) 14 (8) 
Other – n (%) 8 (4) 
MDR bacteria – n % 54 (28) 
Legend: n, number; MDR, multi drug resistant; * cultures were positive in 128 patients 
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Fungal infections were diagnosed in 14 patients. During admission, 26% of patients fulfilled 
ACLF criteria, 36% AKI criteria and 45% SIRS criteria. The most commonly used antibiotics 
were quinolones, third generation cephalosporins and other betalactams in association with 
betalactamases inhibitors; 61 patients (31%) were treated with 2 or more antibiotics (Table 3.3).  
 
Table 3.3. Characteristics of antibiotic treatment during the hospitalization 
Variables N= 199 Duration of treatment 
Treatment with 2 or more antibiotics – n (%) 61 (31) - - 
Time from admission/symptoms of infection to 
antibiotic treatment (hours) – M (IQR) 1.0 (0.5-2.0) - - 
Duration of treatment – M (IQR) 10 (7-19) - - 
Antibiotic class used – n (%) 
   Beta-lactams plus β-lactamases inhibitors 
   3rd generation cephalosporins  
   Quinolones 
   Glycopeptides 
   Carbapenems 
   Lipopeptides 
   Tigecycline 
   Linezolid 
   Aminoglycosides 
   Tetracyclines 
 
72 (36) 
73 (37) 
88 (44) 
42 (21) 
66 (33) 
22 (11) 
10 (5) 
7 (4) 
5 (3) 
1 (1) 
 
7 (6 – 10)  
8 (6 – 10) 
7 (5 – 9) 
8 (6 – 10) 
8 (6 – 10) 
8 (7 – 14) 
10 (9 – 14) 
8 (5 – 10) 
8 (5 – 12) 
7 (- -) 
Antifungal treatment – n (%)* 24 (12) 9 (6 – 13)  
Antibiotic treatment at discharge – n (%) 67 (34) - - 
Legend: n, number; IQR, interquartile range; * antifungal agents used were fluconazole and caspofungin. 
 
The median hospital stay was 15 days (IQR= 9-27 days), the patients were treated with 
antibiotics for a median of 10 days (IQR 7-19) and one third of them continued antibiotic 
treatment at home. Furthermore, 40 patients (20%) were discharged on quinolones prophylaxis. 
Almost all patients had ascites (92%) of which 32% had refractory ascites, and the mean MELD 
score at discharge was 15±5. Among other potential risk factors for frailty and early 
readmissions, 73 patients (37%) had experienced another hospitalization within 30 days before 
the index admission; two thirds of them had a comorbidity other than liver cirrhosis, mainly 
diabetes and chronic kidney disease (CKD), and 8% were discharged in a nursing home facility.  
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CRP levels significantly increased during the acute phase of bacterial infection (22 vs 34 mg/l; 
p<0.001) and significantly decreased at discharge (12.6 mg/L; p<0.001 vs both CRP levels at 
diagnosis and peak; Figure 3.1).  
Figure 3.1. C-reactive protein levels at the diagnosis, during the acute phase of bacterial 
infection and at discharge. 
 
Legend: CRP, C-reactive protein; * p<0.001 vs CRP at diagnosis; §, p<0.001 vs CRP at peak 
 
 
Patients with severe sepsis and/or septic shock (n=52) had significantly higher values of CRP 
both at the diagnosis of infection and at peak than those without (43 vs 18 mg/dl and 65 vs 28 
mg/dl, respectively; both p<0.001). However, levels of CRP at discharge were not significantly 
different between the 2 groups (13 vs 12 mg/dl; p=0.119). We did not find any correlation 
between the CRP levels at discharge and scores of liver disease.  
 
Early readmissions 
Sixty-nine patients (35%) were readmitted to the hospital within 30 days from discharge. The 
probability of readmission at 1, 3, and 12-months was 35%, 67%, and 74%, respectively.  
Table 3.4 shows a comparison between patients readmitted or not within 30 days from discharge.  
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Table 3.4. Characteristics of patients readmitted or not within 30 days from discharge. 
Variables Readmitted (N=69) 
Non-readmitted  
(N=130) P 
Age (years) – m (SD) 62 (14) 61 (13) 0.727 
Gender (male) – n (%) 39 (57) 78 (60) 0.747 
Etiology – n (%) 
  Alcohol 
  HCV 
  HBV 
  Other 
 
24 (35) 
26 (38) 
7 (10) 
12 (17) 
 
58 (45) 
46 (35) 
9 (7) 
17 (13) 
0.517 
Diabetes – n (%) 25 (36) 40 (31) 0.533 
Charlson comorbidity score – m (SD) 4.4 (1.6) 4.5 (2.1) 0.775 
Admitted in the previous 90 days – n (%) 33 (48) 40 (31) 0.026 
Nosocomial infections – n (%) 34 (49) 43 (33) 0.037 
Main type of infection – n (%) 
  Urinary tract infections 
  Spontaneous bacterial peritonitis 
  Pneumonia 
  Skin and soft tissue infections 
  Spontaneous bacteremia 
  Other 
 
27 (39) 
17 (25) 
7 (10) 
7 (10) 
4 (6) 
7 (10) 
 
57 (44) 
19 (15) 
21 (16) 
17 (13) 
11 (9) 
5 (4) 
0.179 
SIRS during admission – n (%) 31 (45) 58 (45) 1.000 
AKI during admission – n (%) 31 (45) 38 (29) 0.040 
ACLF during admission – n (%) 27 (39) 25 (19) 0.004 
Mean arterial pressure (mmHg) – m (SD)* 85 (11) 84 (12) 0.472 
Ascites - n (%)* 68 (99) 114 (88) 0.014 
Refractory ascites – n (%) 24 (35) 39 (30) 0.596 
Hepatic encephalopathy – n (%)* 13 (19) 18 (14) 0.471 
White blood cell count (x 10^9/L) – M (IQR)* 5.9 (3.5 – 7.3) 4.8 (3.4 – 6.9) 0.172 
C- reactive protein (mg/L) – M (IQR)* 16 (9 – 31) 10 (5 – 21) 0.009 
Bilirubin (µmol/L) – M (IQR)* 45 (28 – 71) 39 (21 – 71) 0.144 
INR – M (IQR)* 1.4 (1.2 – 1.6) 1.4 (1.2 – 1.6) 0.954 
Serum creatinine (µmol/L) – M (IQR)* 87 (67 – 114) 75 (60 – 105) 0.021 
Albumin (g/dl) – M (IQR)* 3.0 (2.7-3.5) 2.9 (2.5-3.2) 0.420 
MELD score – m (SD)* 16 (5) 15 (6) 0.114 
Child Pugh score – m (SD) 9 (8 – 10) 8 (7 – 10) 0.043 
CLIF-c AD score – m (SD) 52 (8) 49 (8) 0.049 
Length of hospital stay (days) – M (IQR) 16 (9 – 27) 15 (9 – 27) 0.490 
Duration of antibiotic treatment (days) – M (IQR) 10 (7 – 20) 11 (7 – 18) 0.984 
Antibiotic treatment at discharge – n (%) 20 (29) 47 (36) 0.406 
Norfloxacin prophylaxis – n (%)* 15 (22) 25 (19) 0.815 
Legend: n, number; m, mean; SD, standard deviation; M, median; IQR, interquartile range; SIRS, systemic 
inflammatory responses syndrome; AKI, acute kidney injury; ACLF, acute-on-chronic liver failure; CLIF-c AD, 
Chronic Liver Failure consortium acute decompensation score. *, variables collected at discharge 
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Patients that were readmitted early had a higher rate of ACLF (39 vs 19%; p= 0.004), AKI (45 vs 
29%; p= 0.040), and nosocomial infections (49 vs 33%; p=0.037) during the first hospitalization 
than those who were not readmitted. In addition, patients readmitted early had more frequently 
experienced other hospitalizations in the 30 days before the index hospitalization (48 vs 31%; 
p=0.026). Patients readmitted within 30 days more frequently had ascites (99 vs 88%; p= 0.014) 
and higher levels of serum creatinine (87 vs 75 µmol/L; p=0.021) and CRP (16 vs 10 mg/L; 
p=0.009) at discharge than those not readmitted. No difference was found between patients 
readmitted versus those not readmitted in terms of age, sex, comorbidity, site of infection, 
duration of antibiotic treatment, and/or of hospital stay. The CLIF-c AD score and CTP score 
were significantly higher in those readmitted than in those not readmitted. In a multivariate 
analysis, CRP (OR= 1.91; p=0.022), ACLF during admission (OR=2.48; p=0.008) and a 
previous hospitalization in the 30 days before the index admission (OR=1.50; p=0.042) were 
found to be independent predictors of early readmission (Table 3.5).  
 
Table 3.5. Independent predictors of readmission within 30 days. 
Variables OR 95% CI P 
ACLF 2.48 1.27 – 4.85 0.008 
Admission in the previous 30 days 1.50 1.06 – 2.12 0.042 
CRP at discharge (mg/L) 1.91 1.03 – 3.57 0.022 
Legend: OR, odds ratio; CI, confidence interval; ACLF, acute-on-chronic liver failure; CRP, C-
reactive protein.  
 
 
Patients with a CRP>10 mg/l had a significantly higher probability of being readmitted within 30 
days than those with a CRP≤10 mg/l (44 vs 24%; p=0.007; Figure 3.2). 
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Figure 3.2. Probability to be readmitted within 30 days from discharge according to plasma 
level of C-reactive protein at discharge. 
 
Legend: CRP, C-reactive protein 
 
Forty-seven out of 69 patients (68%) were readmitted early due to an infection. CRP was the only 
independent predictor of early readmission for an infection (OR=1.76; p=0.004). Among patients 
readmitted early for an infection, 25 (52%) were readmitted within 14 days, of which 13 had the 
same infection that had occurred during the first hospitalization. Of the 11 patients readmitted 
within 14 days with positive cultures in both the admissions, the same strain isolated during the 
first admission was found in 8 patients(72%). CRP at discharge was higher in patients readmitted 
within 14 days with the same infection than in those readmitted for a different infection although 
the difference was not significant, probably due to the sample size (28 vs 17 mg/L; p= N.S.). 
 
Analysis of survival 
During the first six months of follow up, 47 patients (23%) died, 19 (10%) were transplanted, 2 
(1%) were lost to follow up and 131 (66%) were alive.  
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A comparison of patients who died versus those who survived at 6 months has been reported in 
Table 3.6. 
Table 3.6. Comparison of characteristics of patients that died versus patients that survived 
at 6 months.  
Variables Survivors (N=131) 
Non-survivors 
(N=47) P 
Age (years) – m (SD) 61 (12) 67 (13) 0.009 
Gender (male) – n (%) 79 (60) 24 (51) 0.353 
Etiology – n (%) 
  Alcohol 
  HCV 
  HBV 
  Other 
 
58 (35) 
46 (44) 
11 (8) 
16 (12) 
 
18 (38) 
16 (34) 
3 (6) 
10 (21) 
0.489 
Diabetes – n (%) 37 (28) 23 (49) 0.017 
Charlson comorbidity score – m (SD) 4.2 (1.9) 5.3 (2.0) 0.001 
Admitted in the previous 90 days – n (%) 44 (34) 18 (38) 0.687 
Nosocomial infections – n (%) 34 (49) 43 (33) 0.410 
Spontaneous bacterial peritonitis – n (%) 17 (13) 10 (21) 0.261 
SIRS during admission – n (%) 56 (43) 25 (53) 0.288 
AKI during admission – n (%) 37 (28) 22 (47) 0.032 
ACLF during admission – n (%) 28 (21) 17 (36) 0.071 
Mean arterial pressure (mmHg) – m (SD)* 85 (12) 83 (9) 0.146 
Ascites - n (%)* 116 (88) 46 (98) 0.073 
Refractory ascites – n (%) 31 (24) 23 (49) 0.002 
Hepatic encephalopathy – n (%)* 21 (16) 7 (15) 1.00 
White blood cell count (x 10^9/L) – M (IQR)* 5.0 (3.3 – 6.9) 5.7 (3.8 – 7.8) 0.127 
C-reactive protein (mg/L) – M (IQR)* 10 (5 – 19) 18 (13 – 32) <0.001 
Bilirubin (µmol/L) – M (IQR)* 34 (21 – 61) 49 (30 – 79) 0.020 
INR – M (IQR)* 1.4 (1.2 – 1.5) 1.5 (1.3 – 1.7) 0.006 
Serum creatinine (µmol/L) – M (IQR)* 76 (60 – 104) 106 (68 – 129) 0.002 
Albumin (g/dl) – M (IQR)* 2.9 (2.5-3.3) 3.0 (2.5-3.5) 0.297 
MELD score – m (SD)* 14 (4) 18 (6) <0.001 
Child Pugh score – m (SD) 8 (7 – 9) 9 (8 – 10) 0.001 
CLIF-c AD score – m (SD) 49 (8) 55 (8) <0.001 
Length of hospital stay (days) – M (IQR) 14 (9 – 26) 16 (8 – 26) 0.971 
Duration of antibiotic treatment (days) – M (IQR) 10 (7 – 18) 10 (7 – 19) 0.614 
Antibiotic treatment at discharge – n (%) 37 (29) 22 (47) 0.038 
Norfloxacin prophylaxis – n (%)* 27 (21) 6 (13) 0.333 
Readmission within 30 days – n (%)* 36 (28) 23 (49) 0.012 
Legend: n, number; m, mean; SD, standard deviation; M, median; IQR, interquartile range; SIRS, systemic 
inflammatory responses syndrome; AKI, acute kidney injury; ACLF, acute-on-chronic liver failure; MELD, model of 
end stage liver disease; CLIF-c AD, Chronic Liver Failure consortium acute decompensation score. *, variables 
collected at discharge; #, Patients transplanted (19) or lost to follow up (2) were excluded from this analysis 
 84 
 
Non-survivors were older, had a higher rate of comorbidity such as diabetes and more advanced 
liver and renal dysfunction than survivors at 6 months. Refractory ascites was significantly more 
common among patients who died than in those who survived at 6 months (49 vs 24%; p= 
0.002). As expected, the CTP, MELD, and CLIF-c AD scores were significantly higher in 
patients that died than in those that survived. CRP levels at discharge were significantly higher in 
patients that died than in those that survived at 6 months (18 vs 10 mg/L; p<0.001). Finally, a 
readmission within 30 days from discharge was significantly more common in non-survivors 
than in survivors (49 vs 28 %; p=0.012). 
In multivariate analysis, age (HR=1.05; p=0.001), MELD score at discharge (HR=1.13; 
p<0.001), CRP (HR=1.85; p=0.001), refractory ascites (HR=2.22; p=0.007), and diabetes 
(HR=2.41; p=0.010) were found to be independent predictors of mortality at 6 months (Table 
3.7). 
 
Table 3.7. Independent predictors of 6-month mortality 
Variables HR 95% CI P 
Age 1.05 1.03 – 1.07 0.001 
MELD score at discharge 1.13 1.07 – 1.18 <0.001 
CRP at discharge (mg/L) 1.85 1.29 – 2.65 0.001 
Refractory ascites 2.22 1.24 – 3.97 0.007 
Diabetes 2.14 1.20 – 3.82 0.010 
Legend: HR, hazard ratio; CI, confidence interval; MELD, model of end stage liver disease; 
CRP, C-reactive protein.  
 
 
Patients with a CRP>10 mg/L had a significantly lower probability of survival at 6 months than 
those with a CRP≤10 mg/L (62 vs 88%; p<0.001; Figure 3.3).  
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Figure 3. Six-months probability of survival according to plasma level of C-reactive protein 
at discharge. 
 
Legend: CRP, C-reactive protein 
 
 
The classification of patients according to the presence of diabetes and CRP with a cut-off of 10 
mg/dl allowed for the identification of groups of patients with a stepwise decrease in survival 
rate. In detail, patients with both DM and CRP>10 mg/dl had the lowest survival rate at 6 months 
(53%) followed by those without DM and a CRP>10 mg/dl (68%), those with DM with a 
CRP≤10 mg/l (75%), while patients without DM and a CRP≤10 mg/l had the best survival rate 
(93%; p<0.001). 
 
Discussion 
The main and most original finding of the study is the strong power of CRP in predicting both 
the 30-day hospital readmission and the 6-month mortality in patients with cirrhosis discharged 
after a bacterial or fungal infection. The finding that high baseline CRP levels could remain 
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elevated over time despite the resolution of a bacterial infection in many patients with cirrhosis is 
not completely new, since it has been already described by Cervoni JP et al.[118]. The new 
finding is the potency of a persistently increased CRP as a predictor of 30-day readmission. 
Remarkably, it was stronger than all the other demographic or clinical parameters when infection 
was considered the only cause of readmission. These findings lead to different potential 
interpretations. From a pathophysiological ground it is well known that CRP is a marker of 
inflammation and an inflammatory state is the main cause of organ failures and thus of ACLF in 
patients with cirrhosis. However, we need to address why a group of cirrhotic patients discharged 
after the resolution of a bacterial or fungal infection maintains high CRP levels.  
The first hypothesis is that patients who had higher levels of CRP at discharge probably had 
higher levels of pathological bacterial translocation. This interpretation is indirectly supported by 
the evidence that patients who were readmitted early to the hospital had a more severe cirrhosis 
as proven by the higher values of CTP and CLIF-c-AD scores at discharge from the index 
hospitalization. However, we did not find a correlation between the levels of CRP and the 
severity of liver disease (MELD score and CTP score). There was a nonsignificant trend toward 
higher levels of CRP in patients with CTP class C (Figure 3.4), a finding already highlighted by 
Papp M et al in noninfected cirrhotic patients[57].  
The second hypothesis is that patients readmitted had a more severe inflammatory response to 
the infection. However, the higher levels of CRP in patients who were readmitted within 30 days 
cannot be accounted for a more severe degree of inflammation at the time of infection, since the 
peak value of CRP during the infection was similar to that observed in patients who were not re-
admitted. 
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Figure 3.4. C-reactive protein levels according to Child-Turcotte.Pugh class. 
 
Legend: CRP, C-reactive protein; CTP, Child-Turcotte-Pugh 
 
Thus, considering all the data, the most likely explanation is that the higher levels of CRP at 
discharge in patients who were then re-admitted could be due to a non-complete resolution of the 
infection. Accordingly, 52% of 25 patients who were readmitted for a bacterial or fungal 
infection within 14 days had the same site of infection, and in 8 patients among 11 with positive 
cultures in both admissions, the same organism has been isolated (72%). The threshold of 14 
days, although arbitrary, was not chosen randomly, since it represents the verge between a 
relapse of infection and a re-infection[119]. Other supporting data are the following: a) the WBC 
count was higher at the time of discharge from the index hospitalization, b) the infection was 
more frequently “difficult to treat” since it was more frequently both nosocomial and/or 
complicated by AKI and ACLF. This interpretation makes it possible to introduce the concept 
that CRP or other biomarkers could be used to guide the antibiotic stewardship strategies, to 
improve the outcomes in patients with cirrhosis. This is a new concept for hepatologists, while in 
other fields of medicine, such as in patients with acute respiratory infections, there is evidence 
that it may be beneficial[120]. Clinical signs such as skin temperature, as well as routine 
laboratory tests, such as WBC count, are probably unreliable in defining the resolution of a 
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bacterial or fungal infection in patients with cirrhosis. In fact, a normal or quite close to normal 
body temperature as well as WBC count within the normal range, cannot exclude the persistence 
of infection. Thus, a CRP value of 10 mg/dl could be used as a target to drive antibiotic treatment 
in patients with cirrhosis and bacterial/fungal infections. Although the duration of antibiotic 
treatment was not standardized in our study, some data may support the concept of a CRP driven 
stewardship of antibiotic treatment. In fact, we found a significant positive correlation between 
the duration of antibiotic treatment and the delta reduction of CRP (peak value – discharge value; 
r=0.310; p<0.001). However, the comparison between CRP-based algorithms with non-
standardized routine care in cirrhotic patients with “difficult to treat” bacterial or fungal 
infections should be performed in a controlled clinical trial, with major end-points such as 28-
day and 3-month mortality rates and 30-day and 3-month hospital readmission rates. 
CRP was also proven to be a strong predictor of a 6-month mortality rate in patients with 
cirrhosis who recovered after a bacterial or fungal infection. The relationship between the 
persistence of an increased level of CRP and the probability of death in patients with cirrhosis 
has already been shown by Cervoni JP et al.[118]. However, they considered a very high 
threshold of CRP, quite close to the median peak value which was observed in the present study, 
and three times higher than the threshold of 10 mg/l at the resolution of the infection that we 
have identified. Nevertheless, looking at the liver related causes of death in their study, one may 
realize that the most common cause was sepsis (44.4%) as it was found in our series (64%).  
In our cohort, diabetes was found to be an independent predictor of 6-month mortality. This 
finding is not a new concept. In fact, diabetes has been shown to be a risk factor of complications 
and mortality in patients with cirrhosis[121]. Interestingly, even in the group of patients with 
diabetes, most of the causes of death were liver-related rather than non-liver-related. The reasons 
of the association of diabetes with complications of cirrhosis is not completely understood, 
however it probably involves changes in microcirculation (microangiopathy), oxidative stress 
and immune dysfunction[122]. In conclusion, CRP or other biomarkers of systemic inflammation 
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could be applied to antibiotic stewardship strategies in order to improve the outcomes in patients 
with cirrhosis who develop a bacterial or fungal infection particularly if it’s difficult to be treated 
because of it is either nosocomial or associated with ACLF. The efficacy of this strategy when 
combined with close monitoring of the frailest patients with cirrhosis in lowering the rate of early 
hospital readmissions should be tested in clinical trials. 
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CONCLUSIONS 
In conclusion, the studies performed in this thesis allowed us to improve the knowledge about 
bacterial infections in patients with cirrhosis. The epidemiology and the spectrum of resistance in 
different countries were partially clarified. The results also showed that the antibiotic treatment 
suggested by the current recommendation has limited efficacy in certain countries and that 
different strategies should be developed in patients with pneumonia and skin and soft tissues 
infections. MDR and particularly XDR bacteria are a big concern and although new molecules 
are currently available for certain strains, their use should be limited to avoid the development of 
further resistance. The results of Study 2 also showed that the new criteria for sepsis, namely 
Sepsis-3 criteria are accurate in defining the severity of infection and thus “sepsis”. These criteria 
may be used to make decisions about the management of patients with cirrhosis and bacterial 
infections both in terms of intensity of treatment and in planning strategies of intervention. The 
drawback of not having a baseline SOFA score has been overcome by the combination of Sepsis-
3 and qSOFA and an algorithm for the use of Sepsis-3 criteria has been proposed. Finally, C-
reactive protein, appear a useful asset to guide the duration of treatment and to predict worse 
outcomes in patients with cirrhosis.  
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